Abstract. In some inflammasomes tumor cells are generated. The internal environment of the inflammasome is conducive to the induction of malignant transformation. Epigenetic changes initiate this process. The subverted stromal connective tissue cells act to promote and sustain the process of malignant trans formation. In its early stages, the premalignant cells depend on paracrine circuitries for the reception of growth factors. The ligands are derived from the connective tissue, and the receptors are expressed on the recipient premalignant cells. The initial events are not a direct attack on the protooncogenes, and thus it may be entirely reversible. Epigenetic processes of hypermethylation of the genes at the promoters of tumor suppressor genes (to silence them), and deacetylation of the histones aimed at the promoters of protooncogenes (to activate them) are ongoing. A large number of short RNA sequences (interfering, micro, short hairpin, noncoding RNAs) silence tumor suppressor genes, by neutralizing their mRNAs. In a serial sequence oncogenes undergo amplifications, pointmutations, translocations and fusions. In its earliest stage, the process is reversible by demethylation of the silenced suppressor gene promoters (to reactivate them), or reacetylation of the histones of the oncogene promoters, thus deactivating them. The external administration of histone deacetylase inhibitors usually leads to the restoration of histone acetylation. In time, the uncorrected processes solidify into constitutive and irreversible gene mutations. Some of the pathogens inducing inflammations with consquential malignant transformation contain oncogenic gene sequences (papilloma viruses, EpsteinBarr virus, Kaposi's sarcomaassociated herpesvirus, hepatitis B and C viruses, Merkel cell polyoma virus, Helicobacter pylori, enterotoxigenic Bacteroides fragilis). These induced malignancies may be multifocal. Other pathogens are devoid of any known oncogenic genomic sequences (mycoplasma vavcarcinogenesis, chlamydia MALTlymphoma genesis). In these cases the host's inflammatory reactions induce the malignant transformation in serial sequences of gene alterations initiated by hypoxia and reactive oxygen and nitrogen species generation. Carcinogenic intrinsic inflammatory processes endogenously initiated without a pathogen are recognized. Chronic inflammatory processes signal the RNA/DNA complex. In response, the DNA may revert into its ancient primordial 'immortal' format, which the clinics recognize as 'oncogenesis'. The DNA remains the ultimate master of bioengineering in order to sustain life. A discussion on the most versatile and resistant primordial RNA/ DNA complex and the pre, proto, and unicellular world in which they coexisted is included.
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tracts. He described the 'ulcéres verruques' in the hotbed of chronic infections (osteomyelitis with fistulous tracts): 'Ulcére de Marjolin sur ostéite chronique'. He became the Membre de l' Académie de Médicine Français, Paris, France. Contemporary histopathology confirms these lesions to be verrucous squamous cell carcinomas, which may originate in any chronic pustulous infected sites ('ulcéres suppurantes'), like in 'hidradenitis suppurativa' or in anal fissures ('papules périanales') and even in gingiva, tongue, and the oropharynx (vide infra).
Rudolf Virchow (18211902) described the inflammatory environment 'Phlogose und Thrombose im Gefässsystem' of malignant tumors ('die krankhaften Geschwülste'). Recently, Virchow was remembered in the Lancet for his early observation (1863) that chronic inflammatory processes accompany, and may even induce, cancers (1) .
Septicemia. The monks 'Brothers of St. Anthony' recognized the high rate of mortality when they attended patients in the 1500's, who suffered hemorrhagic and septic shock after consuming bread baked with Claviceps purpurea infected wheat. The alkaloid ergotamine of the fungus caused severe widespread vasculitis further complicated by septic shock, when guts perforated and peritonitis set in (Fig. 1) (2) . High early mortality might have eliminated those patients who might have increased their susceptibility to late cancers due to suppressor gene silencing or oncogene activations during the acute illness.
Hemorrhagic and septic shock remained an acute complication of the highest mortality in the practice of medicine, especially when combination chemotherapy was introduced in medical oncology/hematology. This author attended patients with hemorrhagic and septic shock at the M.D. Anderson Hospital, University of Texas, Houston, TX, in the 1960's and 1970's (36). Those were the years when a leukemic patient with postchemotherapy leukopenic fevers could die in pseudomonas septicemia with multiple vital organ failures within 24 h.
A major recognition in the pathogenesis of hemorrhagic septic shock is the role of the histone deacetylases. Histone deacetylation is balanced by the activities of histone acetyltransferases that transfer acetyl groups from acetyl coenzymes to lysines (K) within the histone molecules. Histone deacetylases catalyze the removal of acetyl groups from the lysins. Histone deacetylases Class I, II, III, IV are preserved from the yeasts on upward in the evolutionary scale. Class I, II, and IV enzymes are zincdependent and occupy various intracellular localizations. Class III enzymes (sirtuins) are nicotinamide adenine dinucleotidedependent. The genes of histone deacetylases are sensitive to inhibitors (HDACIs), and as such HDACIs exert neuro, cardio, and renalprotective effects in patients with hemorrhagicseptic shock. In the precancerous state, prominent is the activation of the PI3kinase/Akt pathway (phosphatidyl inositol, akt transforming oncogene from thymic lymphoma of Jacob Furth's high leukemia Ak, later Rockefeller Institute AKR, mice), which is frequently activated as a cellsurvival pathway in early events of carcinogenesis. Consequentially to PI3k/Akt activation, insulinlike growth factors (IGF), erythropoietin (EPO) and antiapoptotic cytokines are activated. At the same time HDACIs inhibit Tolllike receptor TLR4, whose response to lipopolysaccharide (LPS) endotoxins is the activation of IL-1β and MyD88 (myeloid differentiation factor/scaffold) and IRAK (IL1 receptorassociated kinase). Further suppressive effects of HDACIs are to the antiapoptotic molecule Bcl2, and the intranuclear transfer of βcatenin, which are frequently activated in early carcinogenesis. The proapoptotic tumor suppressor PTEN (phosphatase and tensin homolog deleted in chromosome 10: 10q23) may be inhibited by HDACIs, but this effect protects cardiomyocytes from apoptotic death. PTEN is an inhibitor of the PI3K/Akt pathway (7, 8) .
Heat shock protein 70 (Hsp70) is induced by HDACIs, thus it exerts its cellprotective and antiinflammatory effects. Member of the large family of chaperone Hsp, Hsp70, may protect proteins in cancer cells exposed to chemoradiotherapy. However, 2phenylethynesulfonamide (PES) inhibits this tumor cellprotective effect (9) . In squamous carcinoma cells, Hsp70 acting as a binding protein to Bcl2associated athanogene1 (Bag1) conveyed apoptosisresistance. Hsp70 and Hsp90 protect metalloproteinase2 in breast cancer cells and assist cancer cell migration and locomotion. Hyperthermia (or fever) mobilized Hsp70 to promote dendritic cell (DC) maturation, macrophage phagocytosis and proinflammatory cytokine (IL8, IL12) production (1012).
Bacterial translocations to mesenteric lymph nodes, liver and spleen occur early in both hemorrhagic and septic shock. Epigenetic gene activations and gene silencing occur in the process. At lysine (K) 4 of activator histone 3, triple methylation (me3) occurs (H3K4me3) and results in silenced posttrans lational modifications. At lysine (K) 27 of suppressor histone 3, triple methylation (me3) occurs (H3K27me3) and results in upregulated posttranslational modifications (13) . Endotoxin (LPS) stimulated TLR4 activates myeloid differentiation factor 88, the scaffold protein (MyD88), IL1β, IL6, IL12 and TNFα. Of the IL1 receptorassociated kinases (vide supra) IRAK1 translocates to the nucleus, where it activates STAT and IL10. Variant IRAK1 haplotype associates with nuclear factor κB (NFκB, the reticuloendothelial virus' conc → vonc, Rel oncoprotein) overactivity; NFκB is liberated, transfers to the Bread baked from wheat infected with Claviceps purpurea contained the toxin ergotamine. Consumption of this bread resulted in extensive severe vasculitis and bowel perforations. These patients died with hemorrhagic and septic shock. The 'suffering man' is in the left lower corner of the painting. In the middle (not shown) St. Anthony is praying over the patient. The monks 'Brothers of St. Anthony' stand behind awaiting for their turn to extend help and care to the dying man. Reprinted with permission.
nuclei and through gene activations releases an excess of pro inflammatory mediators. These events increase the fatal outcome of endotoxin shock (14). Endogenously released alarmins and damageassociated molecular patterns (DAMPs) act as ligands to TLR4. Such endogenous ligands of TLR4 are Hsp70 and some highmobility group box 1 proteins (HMGB). Some of these reactions occur also early in oncogenesis (15). At the clinics, exogenously administered HDACIs antagonize practically all of these reactions (8) . In the patients, it is the HMG protein B1 that performs DNA repair and chromatin modification after DNA damage. However, because of its role in mediating lethal systemic inflammation, HMGB1 is targeted for elimination. In contrast, HMGB1 in protecting against mutagenesis and acting for repairing DNA damage, it reduces or eliminates postseptic shock carcinogenesis, and for these reasons it should be saved (16). Indeed, the rate of postsepticemic oncogenesis does not appear to exceed that of the general population. However, the high mortality and short life span of patients in hemorrhagic/ septic shock might have eliminated those individuals who would have had experienced inflammatory carcinogenesis.
Variant IRAKhaplotypes regulate NFκB activation in sepsis and increased NFκB activity carries higher mortality (14), thus eliminating those patients who suffered oncogene activations. The saffronderived carotenoid, crocetin, suppresses microRNA expression (in rat livers) for tumor necrosis factor α (TNFα), interleukin1β (IL-1β) and inducible nitric oxide synthase (iNOS), thus alleviating the pathophysiology of the condition (17).
In septic shock, LPSstimulated dendritic cells (DCs) excessively produce IL6. MicroRNA 1423p targets an un translated region (UTR) of the IL6 mRNA in DCs and thus reduces IL6 production. Consequentially mortality in septic shock increases. An oligonucleotide (locked nucleic acid modified phosphorothioate oligonucleotide complementary to miRNA1423p) restores IL6 production in DCs and reduces mortality (18) . This report is difficult to comprehend, because it investigated only one pathway of the most complicated events active in septic shock, where IL6 may act parado xically both in pro and antiinflammatory contexts, and miRNA1423p acts also on lymphocytes and macrophages. Further, microRNAs 9, 21, 146, 147, and 155 are also active participants (18).
An interesting corollary is the function of microRNA 1423p in connection with the expression of fusion oncogene mll and its production of oncoprotein MLL (mixed lineage leukemia). The gene derives from the trithorax homologue of the drosophila; its locus in the human genome is at 11q23. It fuses quite promiscuously with various gene segment partners. When fused with AF4 protooncogene segment from 4q31 (asymmetric fmr2 gene; fmr2 = fragile mental retardation), it is associated with the induction of proB cell acute leukemias of newborn infants (1921) . The microRNA1423p targets the 3'UTR (untranslated) fragment of the mRNA from fused gene mll/af4 (17), thus it exerts antileukemia effects.
Epigenetic oncogenesis. Epigenetic events provide a link to oncogenesis and lead to the use of the new terminology 'epige netic field for cancerization' and 'epigenetic switch linking inflammation to cancer' (22). One of the experimental supports for the use of the new terminology comes from the Harvard Medical School. The activation of the src protooncogene triggers NFκBmediated inflammatory response leading to the production of microRNA Lin28 (lin = cell lineage abnormal in the nematode caenorhabditis and upward) and to the down regulation of microRNA Let7 (let = lethal in caenorhabditis and upward). Let7 being an inhibitor of IL6 production, its downregulation leads to increased levels of IL6. IL6 activates the STAT3 pathway and further activates NFκB. STAT is an activator of microRNA21 and miR181b1. These microRNAs inactivate the tumor suppressor genes PTEN and CYLD (23,24) (PTEN = phosphatase and tensin homolog on chromosome ten, 10q23; CYLD = cylindromatosis turban tumor suppressor gene on chromosome 16q12q13).
In inflamed tissues, the short noncoding microRNA155 inhibits the repair of dsDNA breaks, or allows mismatch repairs. These cells assume the 'mutator phenotype' and overexpress hypoxanthine phosphoribosyltransferase to reflect to the excessive number of DNS breaks and mutations. Anti biotics (doxycycline), and LPSinduced inflammatory cytokines (TNF family members, IL1β, IL6, IL8) increase microRNA155 expression in cancer cells. More dsDNA breaks follow. LPSstimulated macrophageconditioned medium imitates the effects of microRNA155. The proliferation rate of adenocarcinoma cells is accelerated by microRNA155. The cell cycle inhibitor Wee (small, in Scottish, by its discoverer Dr Paul Nurse working in Edinburgh), the wee gene product protein, the Wee kinase, is downregulated by microRNA155 (25). Thus, microRNA155 removes the cyclindependent kinase (CDK) mitotic inhibitor, allowing uninhibited cell divisions to proceed. An antisense microRNA155 iRNA (interfering RNA) neutralizes microRNA155. The wee gene product protein WEE reappears and mitoses come to a halt (26). The originally studied Schizosaccharomyces pombe cells with active Wee were non dividing and remained small (wee), whereas the dividing cells (no Wee) were large. The antimitotic tumor suppressor gene wee is often eliminated in human cancer cells (27) . Inactivation of Wee by microRNA155 is one of the mechanisms of inflammatory carcinogenesis (2527).
Among other cancers, microRNA155 is upregulated in breast cancers. Three microRNAs (miR195, miRNA let7a, miRNA155) circulating in the blood of patients are practically diagnostic of breast cancer in 88% sensitivity and 91% specificity (28).
The Argonaute (AGO; the argonautes sailed for king Colchis' Golden Fleece guarded by dragons) family of proteins interacts with mi and siRNAs and form miRNP complexes that regulate posttranscriptional gene expressions. The ancient AGO proteins in archaea and prokaryotes provide defense against intruding elements (phage genomes, retrotransposons). The modern AGO proteins are essential stabilizing core substances of the microRNA siRNAinduced gene silencing complexes (RISCs) (29,30).
The long intranuclear primiRs are processed by the intranuclear enzyme Drosha into 6070 bp hairpin sequences (premiRs). Dicer loads the processed premiR sequences into RISCs. The cytoplasmic Dicer enzyme's (RNase endonuclease) substrate, the shRNAs, and/or the siRNAs are loaded into the AGO proteins. In human cells, Ago2 cleaves the ds siRNA to a ss RNA. The microRNA (miR) duplexes also form RISC complexes. Special miRs are able to neutralize mRNAs traveling into the ribosomes to be translated into oncoproteins (31,32). Nanoparticle cyclodextrin polycations holding siRNAs complementary to the Ewing's sarcoma fusion oncoprotein Ews/ Fli1 (Ewing sarcoma breakpoint region Iflightless I drosophila homolog). In a mouse model of metastatic Ewing's sarcoma, this siRNA inhibited tumor growth (33). The CALAA01 (cyclodextrincontaining polymer, synthetic nanoparticle formulated siRNA, human transferrin ligand aimed at the transferrin receptor) human clinical trial has been approved by the FDA (34,35). The system prevents genomic intrusion, be it viral and/or oncogenic, thus it essentially prevents infection and inflammatory reactions to it, as it destroys the pathogen, be it viral, bacterial, or tumoral mRNAs, before its translation and multiplication.
Cancers originating in scars, chronic fistulous tracts and in lesions of periodontitis. It has been repeatedly observed throughout medical history that burn scars, scars left behind after zoster infections, or small pox vaccinations, chronic purulent fistulous tracts (anorectal, osteomyelytic, nonhealing axillary hidradenitis) may convert in time commonly into 'verrucous' squamous cell, rarely into adenocarcinoma (3646). Unfortunately the genomics of these tumors were seldom if ever studied; only the documented cytological pathology reports are available as classical examples of inflammatory carcinogenesis: arising as verrucous squamous cell carcinomas in the chronic inflammasome.
There is no accepted proof confirming viral etiology (human papilloma virus, Merkel cell polyomavirus) for Marjolin ulcers or verrucous squamous cell carcinomas. In classical Merkel cell carcinomas, sequences of the viral genome are integrated in the host cell genome, and the viral T oncoprotein is mutated. In cutaneous squamous cell carcinomas of immunocompetent individuals, the polymerase chain reaction (PCR) was used for the detection of Merkel viral genomic sequences including those of the T antigen. Merkel polyomaviral infection was detectable in tumors of epidermodysplasia verruciformis, Bowen's disease, and some basal cell and sqamous cell carcinomas, but without T antigen mutations, or proven viral integration. However, in some squamous cell carcinomas, the Merkel polyomaviral genome was integrated, and the mutated T antigen was truncated. This finding was limited to only of 15% (26/177) of the squamous carcinomas tested (4749).
At the Roswell Park Cancer Institute, Buffalo, NY, patients with chronic periodontitis were found to experience an increased incidence of squamous cell carcinomas of the tongue and the oral cavity (50,51). Human papillomavirus carriers were not readily recognized (52), but bacteriological cultures point to a particular pathogen, Porphyromonas gingivalis. P. gingivalis may be dominant, but it is not alone: Chlamydia sp. and Prevotella sp. are also present in chronically inflamed gingival pockets (53,54a). As a fellow traveler, EpsteinBarr virus (EBV, vide infra) was frequently present in lesions of apical periodontitis (54b). P. gingivalis induces matrix metalloproteinase9 (MMP) expression in human oral mucosal epidermal cells and dysregulates the expression of B7H1 and B7DC receptors in human gingival keratinocytes and squamous carcinoma cells (5557 + and invariant iNKT cell generation (5860). The advanced B7 systems are nonexistent in teleost and bony fish that are in possession of the VDJ/RAG/RSS (variable, diversity, joining; recombination activating genes; recombination signal sequences) systems. The advanced B7 and ICOS (inducible T cell costimulator) systems were acquired later in the evolutionary scale (61, 62) .
The epigenetics/genomics of squamous cell carcinoma generation. In head and neck and in particular in maxillary sinus squamous cell carcinomas the microRNAs miR1 and miR133a close to be knocked out. These are tumor suppressive microRNAs and their elimination is essential for successful carcinogenesis. In contrast, transgelin2 and purine nucleoside phosphorylase levels rise in tumor tissues, when miR1 and miR133 are down regulated. 
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-cell infiltration (65) . The tumor suppressor protein, programmed cell death 4 (PDCD4), exerts also proinflammatory effects by upregulating IL6 and NFκB production, decreasing IL10 production, and increasing the mortality of endotoxin (LPS) shock. In contrast, the PDCD4 antagonist, microRNA21, is activated by the LPS/MyD88/NFκB cascade, or by IL6 regulated activation of STAT3; then miR21 exerts antiinflammatory effects. As miR21 downregulates PDCD4, it raises IL10 levels, thus establishing a PDCD4deficient tolerogen internal environment. Other NFκBinduced inflammatory cytokines are TNFα and IL-1β. Other consequences of PDCD4 loss is the activation of the PI3K/Akt 'cell survival pathway' commonly used by cancer cells. If an oligonucleotide knocked out miR21, would the proinflammatory (consequentially procarcinogenic) effects of PDCD increase? The integrity of PDCD could be protected by preserving its mRNA by morpholino 21 (66) .
Both IL1αβ drive squamous carcinoma cells in the head and neck. Especially, cyclooxygenase2 (COX2) is activated. Oncoproteins Snail and Twist promote epithelialto mesenchymal (EMT) transitions of the tumor cells. The Snail oncoprotein activates the colony stimulating factor1 (CSF1), which attracts macrophages; some of these macrophages convert into the M2/tumorassociated macrophage (TAM) lineage. (72) . This is the tumor to whose etiology EBV's latent membrane proteins (LMP, vide infra) with or without the human papilloma virus 16's E6 and E7 oncogenes (vide infra) so decisively contributed.
Transforming growth factor β receptors II and III (TGFβR) are silenced in the epithelial layer and in the carcinoma associated fibroblasts of oral squamous cell carcinomas. TGFβI activates through IL17 an inflammatory reaction in premalignant squamous cell lesions and thus inhibits the growth and metastases of squamous cell carcinomas in the tongue. This very same ligand downregulated TGFβRII and III, thus promoting tumor progression. The dual role of TGFβ consists of inhibitory effects on tumor growth, and/or tumor growth promotion through activation of myofibroblasts of the tumor microenvironment. The tumorassociated fibroblasts (myofibroblasts) produce keratinocyte growth factor (KGF) and matrix metalloproteinase (MMP) for paracrine receptors of the tumor cells. TGFβ ligands (decapentaplegic, from drosophila) activate the downstream mediator smad genes (signaling mothers against decapentaplegic, from the drosophila). Smad signaling operates within the MAPK, NFκB and sonic hedgehog (sHH) network. TGFβ ligands interact with miR192 and miR377, but antagonize miR29a; many more such interactions are awaiting recognition (7376).
Oral cavity squamous carcinoma (OSCC) cells may use an overexpressed autocrine IL6 → IL6R circuitry for their own growth stimulation. The growth of human OSCC xenografts was inhibited by the antiIL6R humanized monoclonal antibody (mcab) tocizilumab. In the treated animals, the STAT3 pathway, and tumordirected neoangiogenesis both were inhibited. Further, MMP9 and IL8 productions were also ablated. Thus, both autocrine and paracrine tumor growth factor circuitries were targeted by the mcab tocizilumab (77, 78) . Other inhibitors of OSCC growth factors are antiIL8 siRNA; and aspirin and bortezomib for the proteasome/NFκB pathways (78) . The strong efficiency of antiinflammatory agents against OSCC proves that inflammatory processes initiate and sustain this tumor. In this case again, it is the epigenetics that initiated carcinogenesis. IL6 induced global hypomethylation of the long interspersed nuclear element1 (LINE1), and executed silencing hypermethylations in the CpG islands of the promoters of tumor suppressor genes CHFR (checkpoint forkhead zink finger domain); GATA5 [for full sense and antisense GATA5M and GATA5U (79)]; and PAX6 (paired box genes) (80) .
Rapidly enlarging OSCC tumor masses extend into avascular and hypoxic environments. These tumor cells can adapt to, and grow, in hypoxic environments. Both hypoxia inducible factors (HIF1 and HIF2) promote tumor cell divisions in hypoxic environments. Patients with tumors showing strong nuclear staining for HIFs experienced shortened overall and tumorfree survivals. Lentivirally encoded antiHIF1/HIF2 shRNA short hairpin antisense molecules 1 and 2 knocked out both HIFs in OSCC xenografts and thus inhibited tumor growth (while shRNAneg control exerted no such effects). The small molecular inhibitor NSC134754 inhibited both HIFs in HippelLindau genedefective kidney carcinomas, thus it should be used for targeting against OSCC (81) .
Amplification of 3q is common in squamous cell carcinomas of mucosal origin rising from 37% to 92% in lung, uterine cervix, esophagus and head and neck (H&N) cancers. The locus of amplification in head and neck squamous cell carcinomas is the 3q2627 region. Against 3% or less in normal mucosa, it rises to 25% in dysplasia and carcinoma in situ up to over 56% in invasive carcinoma. In recurrent carcinomas the copy number of the gene amplifies up to 7290% (82) . The suspected gene is a member of the SOX gene family (SRYrelated high mobility group transcription factor; SRY = sexdetermining region in Y chromosome) (vide infra).
Small noncoding microRNAs (miR) and long noncoding RNAs are highly active in squamous cell carcinomas and in their niches. The downregulated miR489 is a widespectrum suppressor of the activated head and neck squamous carcinoma cell oncogene PTPN11 (protein tyrosine phosphatase non receptor). The cytoplasmic protein PTPN11 operates through two src homology domains (83) . The miR200c in squamous carcinoma stem cells switched off BMI1 signaling (Moloney leukemia virus insertion site; human polycomb gene product protein with tyrosine in its ring finger, instead of cysteine, that inactivates PTEN; degrades ubiquitinproteasome) (84) . When BMI1 was upregulated, miR200c levels were low. Overexpressed miR200c downregulates oncogenes Snail and ZEB1 (zink finger E box) and Ncadherin, but upregulates vimentin and Ecadherin (consequentially inhibiting the liberation and intranuclear transfer of βcatenin). The EMT and metastatic movements of squamous carcinoma cells with upregulated miR200c were inhibited (85) . ZEB1 is the master regulator of EMT (the other EMTinducer gene product proteins are Snail, Twist, Slug); microRNAs miR200abc downregulate ZEB1 (86) .
At the 3p14 locus, the FHIT gene (fragile histidine triad) is deleted, while the epidermal growth factor receptor gene (EGFR) is overexpressed in 50% of squamous cell carcinomas. EGFR coamplifies with CCND1 (cyclin D1) (87) . Oncogenes overexpressed in smokers' squamous cell lung cancers are the SOX2 (vide supra et infra) and BRF1,2 (transcription factor IIIBrelated factor, RNA polymerase III transcription initiator butyrate response factors) at 8p12 (88) . The adenylate and uridylaterich elements (AU/ARE) are present in the untranslated region (3'UTR) of the mRNAs. The AREbinding tristetraprolin proteins (among the BRF1, 2) regulate the expression of cancer or inflammationassociated proteins by attaching to 3'UTRs of mRNAs for their rapid degradation ('mRNA decay') (89) . The mutated BRF genes fail to perform.
In the skin undifferentiated keratinocytes rise from the basal layer up to the differentiated suprabasal layer, where they die to form the stratified barrier lining. The activator protein (AP) transcription factors are part of the complex regulatory process. Inactivation of the AP factors results in hyperproliferation of undifferentiated keratinocytes, which form hyperkeratosis but not tumors (90) . The gene product protein E2F (cyclin E inducer factor) brings about the cyclin/CDK2 complex. The E2F1 mediated activation of p19(INK4D) results in the inhibition of CDK4 and CDK6, bringing the cell cycle to a halt in G1. Thus E2F establishes the INK4/pRB/E2F and p19/(ARF)p53 (alternative reading frame) tumor suppressor pathway (9193).
Inflammationinduced (and other) cancers frequently activate the insulinlike growth factor receptor (IGFR) pathway, which includes the upregulated signaling of the Akt (vide supra) cell survival pathway (94) . Some of the undifferentiated H&N carcinomas with upregulated IGFR were EBV + and/ or HPV + (vide infra) (96) . Two microRNAs (miR7, miR375) target the IGFR1 mRNA, and thus inhibit the growth of squamous cell carcinomas (94, 96) . However, promoter gene methylations of miR375 in tumorbearing patients annuls this effect (96) . Monoclonal antibodies directed at EGFR or IGFR (cetuximab, A12, MK0646, dalotuzumab) exert growth inhibitory effect on squamous carcinoma cell in vivo, also in clinical trials (97, 98) .
Xeroderma pigmentosum (XP). First described by Hebra and
Kaposi and again by Kaposi as such, illustrated, in the Wiener Medizinische Jahrbuch, pp619632, 1882. UV lightinduced subcutaneous inflammation and dsDNA breaks remain unrepaired in patients with germline deficiencies of DNA repair systems (the defective helicases). The ERCC/TFIIH multiprotein multienzyme system carries out the repair of dsDNA breaks (excision repair crosscomplementing; transcription factor for RNA polymerase II and XP helicases). The TFIIH opens the double helix; its enzymes are ATPdependent helicases, 3subunit CDKactivating kinases and the cdk. Polymorphisms of the ERCC/XPD system result in the failure of the nucleotide excision repair genes, referred to as excision repair crosscomplementing repair deficiency, complementation 2 XPD (ERCC2) (99102).
UV lightinduced inflammatory changes and polymorphism in the nuclear excision repair gene complex increases the susceptibility to basal cell carcinoma (103) . In BCC, overexpression of the sHH pathways dominates: HIP (HH interacting protein) overexpression and the deletion of the antagonist dickkopf proteins (from 'fathead' drosophila) dominate. The WNT (wingless, drosophila), Ecadherin/βcatenin and the mTOR (mammalian target of rapamycin) pathways are activated (104, 105) . The sHH system was named after the 17yearold hedgehog escaping from the planet Mobius for continuation of his mischievousness on the planet Earth (Sega video).
The inflammasome
An environment conducive to DNA transformation. These ancient formations are the battlefields between invasive pathogens and the host. Microbial molecules (flagellins; LPSs), and the pathogenassociated molecular patterns (PAMPs), are recognized by the Tolllike receptors (TLRs). Granulocytes and monocytes (macrophages) were the defensive cells in the era of innate immunity; so were dendritic cells and NK cells. Eosinophilic granulocytes were selected out as potential defensive cells against inflammatory carcinogenesis (106) . If so, they may be failing to defend the host against ReedSternberg cells in Hodgkin's disease granulomas (Fig. 2) . The Treg cells surround ReedSternberg cells protecting them against immune T cells (Fig. 3) . Apparently eosinophil granulocytes fail to break through these barriers.
Caspase1 activates the inflammatory cytokines IL1β and IL18 by cleavage into their active form. Alarmin, the high 109113), and all the counteractions of the pathogens, but make no mention just how oncosuppressor genes become silenced and oncogenes become activated within the inflammasomes. However, the figures (cartoons) allow an insight. In the A. Skeldon and M. Saleh paper (111) , the appearance of the antiapoptotic Bcl2 and Bcl XL proteins could protect incipient tumor cells from apoptotic death. In the P.K. Anand, R.K. Subbarao Malireddi and T.D. Kanneganti paper (113), NFκB appears as it translocates from cytoplasm to nucleus. This is a common event in oncogenesis, whereby tumor growth factor cytokine genes are activated. There is very little if any mention of epigenomics; reactive oxygen species and dsDNA breaks, etc. The most complex and not uniform composition of the inflammasome may be carcinogenic, or lymphomagenic. The precise mechanisms of intrainflammasome oncogenesis are not well understood. An attempt at describing these events in the context of inflammatory oncogenesis will be made later in this article.
Mycoplasma oncogenesis. In the mid 1960's, the National Cancer Institute alerted R. Lee Clark, the president of M.D. Anderson Hospital, that reports from European countries (England, France, Germany and Moscow, Russia, then the Soviet Union) claim that strains of Mycoplasmataceae are being frequently isolated from the blood and bone marrow of leukemic patients and that these microorganisms may be etiologic (leukemogenic) agents. The British reports were selected out as the most prominent ones (114, 115) . The reports from Ann Arbor, MI (116) indicated pathogenicity of certain human mycoplasma isolates in mice (toxic deaths, inflammatory conditions, 'leukemoid reactions'). The NCI was to release a substantial special grant for the study of these microorganisms in the context of etiological importance in acute and chronic leukemias. This author was elected to be the principal investigator of the project, based on his earlier publications describing 'pleuropneumonia like growth of bacteria' (117, 118) , which elicited a letter and a citation from Joshua Lederberg (119) , and an expression of interest in the project by Albert Sabin (120) . The pleuropneumonia microorganisms were either true mycoplasmas, or some bacteria growing like pleuropneumonia microorganisms.
A new laboratory was immediately equipped for the growth of mycoplasmas (or pleuropneumonialike organisms, PPLO) from specimens of human origin (saliva, urine, blood, bone marrow) collected and provided for the laboratory by the principal investigator, J.G.S. Florence Pipes was recruited from New Orleans to be in charge of the cultures of these microorganisms. Leon Dmochowski, head of the Department of Virology, appointed his technician Bernadette Borchers to prepare the specimens for electron microscopy studies. The principal investigator (J.G.S.) inoculated several hundreds young suckling white Swiss mice intraperitoneally and/or intravenously through a prominent lateral facial vein for observation. The observation consisted of very frequent inspection for 'general health', palpation of lymph nodes and spleens, periodical examination of blood counts and blood smears of the inoculated mice. Mice succumbed early after inoculations showed 'infectious diseases pathology' without any malignant features. However, practically all other mice remained healthy by one full year. Even after sacrificing many of them for internal examination by histopathology, not one case of leukemia or solid tumor (sarcoma, carcinoma) was observed. The cultures of human sources yielded various strains of mycoplasmas in less than 20% of the patients; some mycoplasmalike microorganisms grew out as bacteria (E. coli) from patients who were receiving an antibiotic when their blood samples were collected. However, the electron microscopic studies showed spectacular pictures of mycoplasmalike microorganisms (sometimes in cases when the cultures were 'no growth'). The principal investigator's (J.G.S.) report at first year's end was in the 'negative'. Neither the Koch postulates could be verified, nor the oncogenic pathogenicity of the cultured mycoplasma microorganisms (like the most frequently isolated M. salivarius) could be proven. In the second year of the project, Dmochowski assumed the position of the principal investigator, as he and Clark suggested to the NCI the need for 'further studies', which remained well financed. In the 4th year's final report of Dmochowski, the conclusion remained in the negative: no leukemo or oncogenicity of the mycoplasma isolates could be documented by the technology applied (121) .
However some 30 years later, a mycoplasma strain, the M. fermentans incognitus, emerged as a suspect coetiologic factor in patients with the acquired immunodeficiency syndrome (AIDS) (122, 123) . Extensive laboratory studies on this strain of mycoplasma eventually failed to show any unique faculties that would distinguish it from the common other strains of M. fermentans (124 (138, 139) .
Chlamydia lymphoma-genesis. These pathogens notoriously induce chronic infections. In old textbooks these agents were mistaken for large viruses (trachoma virus; psittacosis virus, see in Sinkovics' Die Grundlagen der Virusforschung), but the characteristics of their multiplication was recognized to be that of 'intracellular bacteria, or mycoplasma' (117) . Chlamydia sp. notoriously infect the uterine cervix and the prostate (140, 141) . In the uterine cervix, it may coexist with human papilloma viruses (140) .
C. psittaci is a wellestablished etiological agent of human marginal zone and mucosaassociated lymphatic tissue (MALT) lymphomas. The matter was debated 'against versus for' in Blood with evidence supporting more 'for', than 'against' (142144).
Periocular adnexal lymphomas are the most common tumors (145, 146) , but in one case chlamydiacarrier marginal zone lymphoma originated in the choroid plexus of the brain without concomitant periocular involvement. Monocytes/macrophages in the lesions carried the pathogen (147) . Chlamydia antigendriven B cells undergo polyclonal expansion. In this stage oncogenes are not yet activated. The process is reversible by eradication of chlamydia with antibiotics (148) . By MALTlike translocations favoring NFκB activation (vide infra at Helicobacter pylori), monoclonally expanding B cell population(s) emerge (149) . The chlamydia heat shock protein (HSP60) released intracellularly exerts antiapoptotic effect, thus the expansion of the B cell clones continues (150) .
B cell clones with the translocation t(11;18) were free of chlamydia, but the NFκB activation remained constitutive. The involved cell clones suffered mutations or deletions of the A20/ TNFAIP3 gene (tumor necrosis factor αinduced protein; A20 ubiquitinmodifying antiNFκB enzyme at 6q, deleted also in AIDS and EBVrelated lymphoma). The gene product proteins of these genes act as suppressors of NFκB. Further, the promoter of the p16/INK4α gene (inhibitor cyclindependent kinase 4) was silenced by hypermethylation. The cartoon in the cited article (151) shows genetic predisposition, chronic antigenic stimulation of B lineage cells (once rendered constitutive, the B cell proliferation continues after the disappearance of the antigen of chlamydia derivation), two genetic translocations: t(11;18) and t(14;18), p16 alterations, DCinduced helper T cell generation, autoimmune B cell clones, and constitutive NFκB overproduction (151) . With coauthors, this author presented human patients with malignant lymphomas from the clinical material of M.D. Anderson Hospital, in which cases chronic antigenic stimulation (not that of chlamydia) initiated the proliferation of lymphoid cell clones. Some of the antigens were autoantigens and the lymphoid cell clones acted as foreign grafts attacking the host (causing a graftversushostlike autoimmune disease underlying the malignant lymphoma) (152) . If an unidentified chlamydia antigen mimics host cell antigens, even after the disappearance of the pathogen, the immune reactions against that antigen may continue both as an autoimmune disease and as a malignant lymphoma. Thus, periorbital B cell lymphomas occurring in Africa (Kenya), but without chlamydia microorganisms being documented in the lesions (153), they still might have been initiated by C. psittaci. It appears as if chlamydia initiated in vivo an inflammatory process confined to lymph nodes, not carcinogenic, but lymphomagenic.
Tumor cell colonies generated in the inflammasomes
Glioblastoma multiforme (GMF). This highly malignant and radiochemotherapyresistant tumor expropriated the FasL → FasR pathway for driving cell cycle progression (154) . The Fas receptor (FasR) and granulocyte colony stimulating factor (GCSF) encoding gene sequences could be artificially recombined in vitro. Previously, we presumed that such mis matched fusions of broken chromosomes 1 and 10 occur in melanoma in vivo (vide infra). These tumor cells undergo mitoses upon capturing FasL. The microglia and astrocytes interact with tumor cells either in an inhibitory or in a stimulatory fashion. It is usually unknown what agents activate these reactions, especially at the earliest tumorinduction phase. In astrocytes the activated TLR4 induces the ILβ1/MyD88/NFκB signaling pathway resulting in the mobilization of the 'cell survival' MAPK and Jak1STAT1 (janus kinase) chain reaction (155) . Rapidly growing tumors (glioblastoma) advance into hypoxic territories. There, in hypoxic tumor cells, hypoxiainducible transcription factor HIF1α translocates into the nucleus to bind HIF1β. The HIF1αβ dimer induces neoangiogenesis outside the cell and apoptosisresistance within the cell. Further, hypoxia responsive elements (HRE) on inflammatory gene promoters (COX, NOS, PTX, CXCR4, SDF1α) capture HIF1α (cyclooxygenase, nitric oxygen species, acute phase protein pentraxin, chemokine, stromalderived factor). In response, tumor cells proliferate (ᛏ Ki67) and migrate; and resting stem cells undergo activation and enter the cell cycle. These stem cells are vulnerable to malignant transformation instead of differentiation (156) .
Adenosine → adenosine receptor A(1)R interactions suppress glioblastoma growth and cellular invasion. A1AR + microglia cells inhibited the growth and invasion of glioblastoma cells. The nucleoside adenosine derives from the nucleotide ATP. In contrast, A2AR stimulation by its ligand results in the expression of cyclooxygenase2, prostaglandin and nerve growth factor (NGF). Activated A1AR suppresses MMP production in the tumor (157) . These tumors contain microglia cells and macrophages and originate from stem cells (158) . In addition to up to 30% microglia in the tumor mass, and some subverted not transformed astrocytes also provide tumor growth factors (159) . One of the growth factors is TGFβ acting through its receptor TGFβIIR. Small hairpin complementary shRNA in a plasmid downregulated expression of the receptor, and thus reduced tumor cell growth and invasiveness in nude mice (160) .
J.C. Horvath and this author submitted a hospital surveillance committeeapproved protocol for the immunotherapy of GMF with viral oncolysatestimulated immune T lymphocytes and lymphokineactivated NK cells (LAK cells), which was not funded, for those clinical investigators, who possibly could obtain the financial support (161) . This article provided a review on the interactions of astrocytes and microglia with the tumor cells (based on work being carried out up to 2006 at M.D. Anderson Hospital). It concluded that after the eradication of the tumor bulk by surgery and radiotherapy, it will be immunotherapy that will prevent the relapse with resistant tumor cells. At M.D. Anderson and elsewhere, a vaccine of bone marrowderived dendritic cells pulsed with tumor homogenates was recommended (162, 163) . A genetically engineered oncolytic adenovirus was another choice (reviewed in ref. 164 ). The splice variant of the epidermal growth factor receptor EGFRvIII vaccine was already in its earliest clinical trials. The article (161) recommended a viral oncolysate vaccine subcutaneously, and adoptive immune T cell/NK cell therapy to be administered through an Ommaya reservoir into the tumor bed. In support, it was known that the brain readily accepted extravasated immune T and NK cells (165167). NK cells attack glioblastoma cells (168, 169) . However, TGFβ inactivates NKG2D cells (170) . Inflammatory events are essential in the induction and sustenance of glioblastoma. These events are supported by the alleviating effects of antiinflammatory drugs on the clinical course of this malignancy. Nonsteroidal antiinflammatory drugs activate the genes NAG1 (nonsteroidal antiinflammatory drugactivated gene), and growth and differentiation factor (GDF15) in glioma cells. NAG1 is usually silenced by dense methylations of its promoter; demethylation restores NAG1 (173) . NAG could stop migration and induce apoptosis (with troglitazone) of tumor (gastric cancer) cells (174) . The distant TGFrelative, GDF, may be unpredictable: GDF15 reduced susceptibility of HER2/neu + breast cancer cells to trastuzumab, and GDF9 induced EMT in prostate cancer cells (175) .
Inflammatory changes in the cerebrum bring about and sustain an incurable tumor of the highest lethality, and of chemoradiotherapy resistance. The most complex genomics of glioblastoma exhibit somatic mutations and loss of heterozygosity in its numerous oncogenes. The plateletderived growth factor and VGF are upregulated; tumor suppressors p53, RB and CDKN (cyclindepedent kinase inhibitor) are deleted (176) . An Achilles heal of this tumor is revealed by its epigenomics. The oncosuppressor microRNAs487ab are downregulated and the oncoprotective microRNA502 and microRNA532 are upregulated. Two other microRNAs (miR175p and miR106a) are related to tumorigenesis and survival (177) . Could the onco protective miR502/532 be attacked by complementary siRNAs? Will targeted therapy (suppression of PDGF with imitanib, VEGF with bevacizumab, iNOS with mercaptoethylguanidine, cyclooxygenase with sulindac sulfide, or indomethacine, etc.) induce remissions, which could be maintained with the immuno therapeutic modalities (vaccines and adoptively administered immune T lymphocytes and LAK cells), which, however, unfortunately seldom if ever are supported outside the NIH/NCI (161) .
Papillary carcinoma cells of the thyroid release inflammatory cytokines.
The pathogenesis of Hashimoto's autoimmune thyroiditis and its consequences of B cell lymphoma or papillary carcinoma have recently been reviewed, but without being able to recognize the initiator(s) of these conditions (178) . The customary chain of events is followed: DCs recognize thyroglo bulins and thyroid peroxidases, instruct CD4 + T cells to engage B cells to produce antibodies. The expanding B cell population first is polyclonal, until after one MALTlike B cell clone emerges for monoclonal expansion. In the background, because of CTLA4 (cytotoxic T lymphocyteassociated antigen 4) gene polymorphism, the inhibitor of autoimmunity becomes deficient. The autoimmune B cell clone shows some rearrangement of its IgM heavy chain locus and may undergo the translocation t(8;14) (q24;q32). Apparently no Treg clones rise to inhibit the proliferation of the autoimmune B cell clone (178, 179) .
The fusion oncoprotein RET/PTC (rearranged transformation papillary thyroid cancer) is formed and the MAPK signaling pathway is activated. Elevated levels of nitric oxide synthases (NOS) increased NO levels; vascular endothelial growth factor and its receptors VEGFR1, 2, angiopoietin2 and its receptor Tie2 were overexpressed; so was the endothelin1 pathway (180) . The RET oncoprotein activates inflammatory genes within thyrocytes; these are the granulocyte/monocyte growth factor, IL-1β, cyclooxygenase2, chemokine ligands 2 and 20, IL8 (chemokine ligand 8), chemokine receptor 4 (CXCR4), extracel-lular matrixdegrading enzymes and lymphocyte selectin genes, mRNAs and gene product proteins. NFκB and transforming growth factor β (TGFβ) levels are high and protect tumor cells from apoptotic death. The activated STAT pathway drives tumor cell replication and inhibits DC maturation, thus immature DCs establish a tolerant Th2type internal environment (181) . The presence of CD4 + CD25 + FoxP3 + tumorassociated lymphocytes allowed larger tumors and their locomotion to form lymph node metastases (182) .
Further pecularities in autoimmune thyroiditis, the thyroid lymphoma and carcinoma are that: i) The background immunologic milieu of the host is Th1type, so much so that the inducer T cell clone may turn malignant. The malignant T cell clone was CD8 -but CD3 + CD4
+ TCR + and chemokineproducer (CXCR + CCR5 + ) (183) . In contrast, is it not so that the antibody producer B cell clone is the product of a Th2type environment? ii) A combat of the reactive lymphocyte clones results in the appearance of many apoptotic cells (184) . The question is who are the killers and who are the victims? iii) The inhibitory signals against autoimmunity derive from the CTLA4 pathway of T (and B) lineage lymphocytes. However, the CTLA4 pathway does not appear inactivated, even soluble CTLA4 receptors circulate and are able to react with their ligands CD80/86 (185) . Yet autoimmunity occurs and culminates in a B lineage lymphoma. There is an effort to block CTLA4 with ipilimumab to induce autoimmunity against tumor cells (melanoma) masquerading for exemption and acceptance as self. However, in an environment of autoimmunity already in existence, papillary carcinoma cells are able to arise and prevail. These questions remain unanswered even in the best and most recent texts (186) . The papillary carcinoma cells release the inflammatory cytokines (181) . The situation in Greaves' autoimmune hyperthyroidism is better understood. There, autoantibodies to the overexpressed thyroidstimulating hormone receptor (TDHR) and decreased Treg cells in number and function cooperate with IFNαproducer plasmacytoid DCs that cause apoptotic death of the Treg cells (187) . It is still unclear what inflammatory process activates the plasmacytoid DCs in the first place: may be an endogenous retrovirus?
Barrett's esophagus and esophageal adenocarcinoma. Barrett's esophagus (BE) is a premalignant condition consequential to chronic gastroesophageal reflux disease (GERD). BE may be viewed as an inflammasome, which harbors a chronic inflammatory process and the germline mutations of one or all three suspect genes: macrophage scavenger receptor1 (MSR1, locus at 8p22); adenosquamous cell carcinoma1 (ASCC1, locus at 10q2122); and collagene triple helix repeat containing1 (CTHRC1, locus at 8p22.124.22). MSR1 mutations are frequently of somatic, and occasionally of germline causation. MSR1 mutation leads to upregulation of the cyclin D1 gene both in adeno, and squamous cell esophageal carcinomas (CCND1) (188190). The major inducer of the inflammatory reactions is deoxycholic acid (DCA); its effects on esophageal carcinoma cell lines (squamous cell carcinoma HET1A, adenomatous carcinoma SKGT4) were studied in vitro. DCA induced IL8 in both, and IL1αβ in the adenomatous cell line (191) . The tribbleshomology3 (TRB3) gene (a gene controlling mitogenactivated protein kinase cascades) (191, 192) , was induced in the squamous, and silenced in the adenomatous cell line; it was suppressed in most other esophageal carcinoma cell lines in silico. It could be experimentally silenced by small interfering RNA (siRNA) preparations. Reinduction of the TRB3 gene into the adenomatous cell line resulted in the release of NFκB, a cytokine known to activate inflammatory cytokines upon its intranuclear translocation (190, 191) . In BE active are IL6 and signal transducer and activator of transcription (STAT) (192, 193) , oxidative stress inducible NO synthase (194) , cyclooxygenase2 (195) , and prostaglandins (196) . In BE, inflammatory gene expression is associated with the activity of miRNA375. Poor prognosisassociated lymphokines were IFNγ, IL-1α, IL8, IL21, IL23. Coexpression of miRNA375 improved the prognosis, so did expression of the proapoptotic and cell proliferation inhibitor annexin1 (ANXA1), which was inhibited in most esophageal tumors (197) .
In the benign stage of Barrett's esophagus, the artificial induction of intracellular acidification elicited the appearance of reactive oxygen species (ROS) followed by doublestranded DNA breaks. These were detected by immunofluorescence for histone H2AX phosphorylation and were prevented by pretreatment with isothiocyanatestilbenedisulfonate or acetyl Lcysteine.
Nonrepaired dsDNA breaks are considered to be precancerous events (198) . MicroRNAs intervene in esophageal carcinogenesis. In comparison with healthy and cancerous tissues, downregulated microRNAs in the cancer tissue are considered to be tumor suppressors lost, whereas upregulated microRNAs are suspect cancer inducers. Elevated level of miR21 in noncancerous tissues of patients with squamous cell carcinoma, and reduced levels of miR375 in cancerous tissues of patients with adenocarcinomas foretold adverse clinical course. This review describes the microRNA technology (isolation and quantification) in good details. The very valuable Fig. 2A of the cited article compares adenocarcinoma cancerous tissue and noncancerous tissue levels (with a typographic error overlooked by the editors): in tumor tissue overexpressed were miR21, miR223, miR192, and miR194; underexpressed was miR203. In Fig. 2B , squamous cell carcinoma tumor tissue overexpressed miR21 and underexpressed miR375. In Fig. 2A , miR375 is not mentioned in connection with adenocarcinomas, but in the conclusion it is pointed out to be an adverse prognostic factor for BEassociated adenocarcinomas (199) .
Pancreatic adenocarcinoma. Chronic pancreatitis leads to adenocarcinoma induction. In Romanian patients studied at Haţieganu Medical School in ClujNapoca (Kolozsvár), Transsylvania, TNFα and IL6 are the dominant cytokines in that condition. In the malignantly transformed tissue, IL8 and macrophage inflammatory protein3α appear in elevated levels (200) . In tumorigenesis of the gastrointestinal tract, TGFβ first exerts antiinflammatory and antioncogenic effects. Once a malignant tumor is generated, TGFβ becomes its supporter by promoting its invasion and metastases, and by subverting its stroma for the production of cytokines with paracrine circuitries to receptors of the tumor cell (201) . For example, fibroblasts of the pancreatic cancer's microenvironment secreted neuregulin1 for the phosphorylation and thus activation of Erb3 (epidermal growth factor receptor) and AKT (activated kinase transforming/ thymic, also known as protein kinase B) signaling pathways in the tumor cells. Erlotinib and the Erb3directed mcab MM121 shut down this pathway and halted the growth of pancreatic cancer xenografts (202) . The sHH oncogenic pathway is active in pancreatic cancer cells. Here stem cell gene product proteins Nanog, cMyc, Oct4 (nanogs were the celtic people remaining eternally young, avian myelocytic leukemia oncogene, octamer binding motif) drive tumor cell growth. A laboratory product small hairpin shRNA is inhibitory to Nanog. Natural products epigallocatechin3gallate and quercetin synergistically inhibited the sHH pathway and by overcoming Bcl2 and XIAP (Xliked inhibitor of apoptosis) promoted tumor cell death (203) . A masterfully constructed cartoon depicts the oncogenic genome within pancreatic cancer cells and the cancersupporting and inflammatory and immunoevasive activities (cyclooxygenase, prostaglandin, and VEGFproduction, Treg cells, myeloid derived suppressor cells and tumorassociated macrophages) of the tumor's microenvironment (204) . The tumor cell itself exerts effective immunoevasive maneuvers. Supernatants of pancreatic cancer cells inhibit CD4 T cell proliferation and migration, but induced (failed to inhibit) IFNγ production. However, allowed CD69 + lymphocyte subset expansion (205) . The cluster of differentiation marker CD69 characterizes most NK/NKT cells and as such it regulates CD17 lymphocytes in establishing Th17 type immune environment (206) . In imitating Treg cells for the neutralization of immune T cells, pancreatic cancer cells are able to express Fox3 under the inducing effect of TGFβ2. When siRNA suppressed Fox3 expression, the cancer cells secreted IL6 and IL8 (that were suppressed when Fox3 was expressed). Mimicking Treg, pancreatic cancer cells antagonized immune T cell clonal expansion (207) .
The lectin galectin3 is targeted by matrix metalloproteinase7 (MMP7, matrilysin). MMP7 levels are high in the blood of patients with pancreatic adenocarcinoma. In mice STAT3 dictates the pace of pancreas adenocarcinoma cell divisions and MMP7 expression (208, 209) . The ZIP4 protein (zink transporter protein; Zrt/Irtlike protein: zink/iron responsive transporter) works with IL6 and STAT in stimulating pancreatic cancer cell growth; silencing it with shRNAs inhibits cancer cell growth (210, 211) . Of cancer cells growing in holo, mero, and paraclones, it is the holoclone stem cells that are most chemoresistant, express most of the stem cell genes and corresponding microRNAs and yield most of the tumorinitiating cells (212) . In pancreatic ductal adenocarcinoma cells miR155 targets and destroys the tumor suppressor p53induced nuclear protein 1 (TP53INP1). Next, the tumor metastasis suppressor E1Abinding protein (EP300) is neutralized by miR194, miR200b, miR220c and miR429.
The tumor suppressors DPC/Smad4 (DNApicked chro matin; signaling mothers against decapentaplegic; decapentaplegic = TGFβ ligand) are knocked out by miR421 and miR483. The miR132 and miR212 inhibit the binding and neutralizing the E2F protein by RB. The NFκBrepressing factor (NKRF) is neutralized by miR301, thus liberating NFκB. The 'sprouty homolog' of drosophila, Spry2, is neutralized by miR27a. The tumor suppressor inhibitor of growth protein ING4 is targeted for neutralization by miR214. In contrast, those miRs that may act as tumor suppressors (miR34, a p53 activator; miR96, a Kras inhibitor; miR375, a proapoptotic stimulator by inhibiting 143ζ and downregulator of Akt; miR15a, a wingless drosophila Wnt/βcatenin and fibroblast growth factor7 inhibitor) (213) remain silent in the inflammatory carcinogenesis process within the pancreas. A detailed tabulation of up and downregulated microRNAs in pancreatic cancer with literature citations was made available (214), both references from M.D. Anderson Hospital (213, 214) .
In the human genome, the promoter gene of the inflammatory cytokine IL1β undergoes single nucleotide polymorphisms (215) , that alone without a specific pathogen may initiate an inflammatory process. The stimulated IL1 signaling pathway upregulates the tumor promoters nicotinamide phosphoribosyl transferase and prostaglandin H2 synthase in human pancreatic cancer cells (216) .
Oncogenesis in the pancreas shows how an inflammatory process can trigger a cascade of oncosuppressor gene silencing and oncoprotein activation, and that the DNA is a willing partner in the plot. It appears as if in an ancient crosstalk resumed, the RNA mobilizes its forces to rescue the DNA from a host threatened with an impending demise (vide infra).
Inflammatory breast cancer. Lymphangitic locoregional spread of tumor cells results in the occlusion of lymph channels causing the 'peu d'orange' cutaneous edema. However, there is redness, warmth and pain. No infectious pathogens are present (negative stains and cultures). The host defensive reactions are dominated by scanty monocyticlymphocytic infiltrates; no eosinophils, no granulocytes, no purulence. It appears to be an endogenously activated inflammatory process ('intrinsic inflammation') without any explicitly recognizable external pathogen. The breast cancer associated BRCA genedefective cancer cells can not repair, but live with, dsDNA breaks. The repair enzyme polyadenosine diphosphate ribose polymerase [PARP, to be distinguished from PPAR, the peroxisome proliferator (vide infra)] would initiate ssDNA strand repairs. However, PARP inhibitors (olaparib, and the antiinflammatory cordycepin) send BRCAmutated breast cancer cells through the apoptotic death pathway.
In a murine breast cancer model, leptin activated the Notch signaling pathway and IL1 and VEGF/VEGFR2 overexpression (217) . The thymic stromal lymphopoietin (TSLP, a IL7like type 1 inflammatory cytokine signaling through TSLPR in CD4 + cells and thus inducing IL10 and IL13 production for a Th2type host immune environment) promotes the progression of breast cancer cells both by lymphatic and vascular routes. Inactivation of TSLP in a mouse model, resulted in the cessation of all tumor metastases (218) . The inflammatory cytokine, TNFα promotes the growth of HER2/neuT breast cancers in mice. Deprivation of TNFα resulted in disarranged tumor vasculature and conversion of Th2type to Th1type inner immune environment (unexpected, as TNFα with IFNγ are classical inducers of the Th1type inner environment) (219) . The relevance of these pathways to human breast inflammatory cancers is unknown. However, TNFα308 polymorphism comes with reduced breast cancer incidence in Caucasian women (220) . The polycomb protein, zeste homolog2 (EZH2) is overexpressed in human inflammatory breast cancer cells with cell cycle progression resulting. Patients with zesteexpressor inflammatory breast cancer cells had short survivals (221) . ErbB1/2 overexpression is also frequent in inflammatory breast cancer cells. The patented lapatinib analog GW583340 induced cytoplasmic ROS (vide infra) formation with apoptotic cell deaths following; these effects were reversed by superoxide dismutase (SOD). Inflammatory breast cancer cells with elevated levels of SOD and glutathione resisted apoptotic deaths due to no H 2 O 2 (ROS) formation upon treatment with the lapatinib analog or paraquat (222) .
The infiltration of human breast cancers with CD8 + T lymphocytes is correlated with better prognosis (223) . However, a subclass of CD8 + T cells, appears to promote lymphangitic spread of human breast cancer cells toward regional (axillary) lymph nodes. These breast cancer cells undergo EMT. The lymphocytes are of the ILEI subclass (interleukinlike EMT inducers). This subclass of T lymphocytes expresses TNFα and TGFβ and needs the cooperation of mutated Ras and Snail oncoproteins in the tumor cells (224) . This author proposed the terminology of traitor/transforming T cells (T/T T) for this subclass of lymphocytes (225) . However, no matter how attractive it is to presume it, it is not known if the T/T T subclass of lymphocytes induces the inflammatory type of breast cancer. In cooperation with chemokines CCR4/CCL22, DCactivated and tumor antigenspecific CD4 + Treg cells infiltrate breast cancers and contribute to the cancer's immunosuppressive process (226a).
Gene sequences related to the mouse mammary tumor retrovirus (Bittner virus) occur in human breast cancers (226b), but further proof is needed for the causative, and/or inflammationinducing effects of these agents. Many human tumors (teratocarcinomas, melanoma, ovarian adenocarcinoma, and malignant lymphomas express endogenous retroviruses, but without solid proof for etiologic connections (225) The M.D. Anderson team recognized a chain reaction with the proinflammatory TNFα activating IKKβ (I κ kinase), which then inactivated the cancer suppressing complex of TSC1/TSC2 (tuberous sclerosis), which usually acts by holding down mTOR. NFκB gets liberated in the process and transits from cytoplasm to nucleus to activate inflammatory and potentially oncogenic genes (229, 230) . A comparison of the genomics of inflammatory and noninflammatory breast cancers revealed overexpression of immune system and mTOR pathways in inflammatory breast cancers (231) . The Michigan Comprehensive Cancer Center found overexpressed EGFR and disabled p53 genes. More significantly, the RhoC (Ras homolog) GTPase GTPbinding protein gene was overexpressed in 90%, whereas the Wisp3/ LIBC tumor suppressor gene (Wntinduced secreted protein, from wingless drosophila; lost in inflammatory breast cancer) was deleted in 80% of the specimens examined (232) . In France, those inflammatory breast cancer stem cells that overexpressed aldehyde dehydrogenase (ALDH) metastasized most frequently. Graphs show high rate of mortality in ALDH + inflammatory breast cancers (233) . However, noninflammatory breast cancers expressing ALDH also run an adverse clinical course.
Breast cancer stem cells' DNA is highly oncogenic showing 100 to 1,000fold increased tumorigenicity in xenografts, more than that of the general cell population of the MCF7 (Michigan Cancer Foundation) established cell line (vide supra). The stem cell phenotype is ESA + CD44 + CD24 +/low (epithelialspecific antigen). The oncogenic stem cell DNA is highly chemoresistant. The cell line under the effect of miR27b overexpresses the drugmetabolizing enzyme CYP1B1 (cyclophilin). The active miR21 targets the mRNAs of tumor suppressor genes tropomyosin (TPM1) and PDCD4. The tumor promoter gene pleomorphic adenoma (PLAG) is targeted by miR200a and miR224 and the activities of these miRs are curtailed in the oncogenic stem cells (234) . A report names six microRNAs that are overexpressed (miR335, miR3375p, miR451, miR4863p, miR520a5p, miR548d5p) and seven microRNAs (miR1a, miR24, miR29a, miR30b, miR320, miR3425p, miR3423p), that were downregulated in inflammatory carcinomas of the breast. However, the exact genomic origins of most of these miRs have not as yet been pinpointed (235) . Inflammatory cytokines IFNγ, IL6, LPS endotoxin, and poly(I:C) activate microRNA155 in breast cancer cells; miR155 then activates the STAT and JAK (Janus kinase) 'cell survival' pathways connecting inflammatory immune stimulation with the inception of oncogenesis (236) .
The inflammatory COX2 expression appears early: already active in ductal carcinoma in situ (DCIS), catalyzing arachidonic acid to prostanoids. Its inducer is 12myristate 13acetate that could be blocked with the flavonoid apigenin (237,238).
The very rare incidence of anaplastic large cell lymphoma (ALCL) beneath silicone breast implants occurred in women receiving the implants for cosmetic reasons (not after maste ctomies for breast cancers). The lymphoma cells are ALK 
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-T cells of defective T cell receptors. The lymphoma cells express the antiapo ptotic myeloid cell leukemia1 protein (MCL1) controlled by microRNA29 (it suppresses MCL1 expression). In ALCL, low miRNA29 levels allow high expression of MCL1 (providing protection against apoptosis). It is presumed to be induced by unidentified cytokines from histiocytes reactive to silicone particles (239241).
Nonsilicone implantrelated ALK + anaplastic large cell lymphomas overexpress the antiapoptotic MCL1 protein (while Bcl2 is silent). The MCL1 protein is under the control of microRNA29a: in ALK + ALCL miR29a levels are low due to methylations of the miR29a gene, thus MCL1 is liberated. In this lymphoma the nucleophosmin (NPM) and ALK genes fuse: t(2;5)(p23;q35), thus creating the NPM/ALK oncoprotein (NPM is nuclear phosphoprotein B23 numatrin). The NPM/ ALK oncoprotein activates the PI3K/Akt and mTOR pathways; the reaction chain continues in the constitutive activation of signaling from sHH/GLI (sonic hedgehog; gliomaassociated oncogene homolog) (242, 243) .
Colonic polyps and adenocarcinoma. The classical 'Vogelgram' describes the sequential gene deletions, mutations and fusion oncoproteins that lead to the transformation of colonic polyps into adenocarcinomas (244) . In this scheme, peroxisome proliferatoractivated receptor δ (PPARδ), a potential tumor promoter, responding to its natural ligands of fatty acids prostacyclins/prostaglandins and active in inflammatory processes, is suppressed by the product of the adenomatous polyposis coli gene (APC), whose tumor suppressor pathway consists of APC/βcatenin/T cell factor4 (TCL4). This pathway is lost to mutations and deletion at 5q21. In the healthy tissues, the APC gene product protein inhibits the complex formation between βcatenin and TCL4. Among others (cMyc), PPARδ is another target of the βcatenin/TCL4 complex (the PPARδ promoter contains the TCL4 binding sites). PPARδ mRNA levels are high in colorectal tumor tissues, but suppressed by the functional APC. Deleted (or lost to mutation or silencing) are at 17p the pro apoptotic p53, the Waf1/CIP1 (wildtype p53 activated fragment; cycline kinase inhibitory protein) at 21p, the Dickkopf, the Wnt antagonist, the colon cancer suppressor gene (DCC) at 18q21, the nm23, the nonmetastatic gene at 17q21, and the mutated colorectal cancer gene (MCC) at 5q. Pointmutated is at 5q in its codon 12 the Kras with activation of cMyc at 8q24. Loss of heterozygosity at 5q21 involves the APC/MCC genes (244247).
The colonic polyps are 'inflammasomes' expressing great histiocytic, leukocytic and mast cell activities; CXCL12 (stromal derived factor, chemokine) switches from IL10 to IL17 and from anti to proinflammatory Treg cells. The advancement of adenomas (polyps) into adenocarcinomas is through an 'inflammatory phenotype' characterized by attraction of leukocytes and macrophages into these lesions by IL8. Knockout of the proapoptotic p53 gene secures cell survival. Paracrine neovascularization is elicited and activation of the cell motility processes by chemokines (CCL20toCCR6; upregulation of cyclooxygenase2 by CXCL1) initiate the process. Activation of 'cell survival pathways' (STAT, MAPK, PI3K/Akt) overcomes the opposing forces of MyD88 and IL18 driving the cell to the stage of no return, that is, the switch of stem cell genes away from differentiation to immortalization (recognized clinically as 'malignant transformation'). The proinflammatory genes involved, many TLRs (especially TLR4), and chemokine genes originating from the innate era, are identified: CXCL1, CXCL2, CXCL3, IL8, CCL5. CCL19, CCL20, CCL21, CCL23, CCL5; and inflammatory iNOS + macrophages are activated (248253). However, Hanahan and Weinberg omitted inflammatory contributions from the list of carcinogenic events. Mantovani et al supplemented trait number 7: inflammatory carcinogenesis (254256).
At the Semmelweis University, Budapest, Hungary, a major engagement is underway for the elucidation of key mechanisms in colonic carcinogenesis (257) . What goes wrong in the lymphoid follicles receiving stem cell supplements for the regeneration of the colonic mucosal lining? The colonic epithelial cell layer is shed and regenerated by an upward flow of new cells in the crypts in rapid successions. The gutassociated lymphatic tissue (GALT) is dispersed as isolated lymphatic follicles (ILFs). ILFs receive bone marrowderived stem cells (BMDSC) through their blood and lymphatic vascularization. In ILFs, the resident multiple lymphoid elements, dendritic cells, and syncytia of myofibroblasts encounter and interact with the arriving BMDSCs. The ILFs preserved innate immune faculties and as such, are immediately reacting through TLRs. For the repair of mucosal bowel wall damage, ILFs initiate the mobilization of epithelial cells in the crypts (257, 258) . The contact between ILF cells and epithelial cells is through the WntLgr5 (wingless in drosophila; leucinrich repeat containing G proteincoupled receptor 5) pathway. Lgr5 is overexpressed in metastatic colorectal cancer cells. These cells undergo EMT, either by mobilizing their own Twist and Snail gene product proteins, or by fusing with subverted tumorassociated macrophages (257260). The colonic mucosa continually is at an inflammatory alert (252, 256) , that facilitates the switch diverting from the regenerative function in the stem cells, to the process of immortalization (malignant transformation), upon repeated intake of nutritionally introduced chemical toxins.
The commonly present LPSs and TNFα readily activate REL/NFκB. The gene of this ancient transcription factor was discovered in a strain of the avian reticuloendothelial virus (crel → vrel). NFκB upregulates TGFRβII. In colon cancer cells NFκB is constitutively activated. When the NFκB upregulator IκB kinase γ was knocked out by iRNA, tumor cell xenografts regressed (261, 262) , The tumor suppressor oncostatin M (OSM) is silenced early in colonic polyps and colon carcinomas. When active, OSM reduces tumor cell proliferation, induces differentiation or apoptosis. It is neutralized by DNA methylation, or histone deacetylation. Methyltransferase inhibition (5azadeoxycytidine) and histone reacetylation (deacetylase inhibitor, trichostatin) reactivated OSM in colon cancer cell lines (263) . The microRNA137 acts as a colon cancer cell suppressor, but early in the process of carcinogenesis, CpG islands of its gene are hypermethylated and thus silenced (264) . In contrast, microRNA21 interacts in a mutual stimulatory way with inflammatory events (IL6, IL8, IL12a, the tolerogen IL10, and with the genotoxic NOS2). These actions spelled out a high inflammatory risk score and cancerspecific mortality (265) . In mice, inflammation in the bowels mediates the methylation and silencing of the polycomb target genes (for example, lysine 27 on histone 3 was trimethylated) (266) . In contrast, reacetylation of histones by histone deacetylase inhibitors (DHDACI, vide supra) could induce intrinsic (mitochondrial) apoptosis of colon cancer cells (267) . In Shanghai, P.R. China, a genetically engineered adenovirus delivers the XIAPassociated factor 1 gene (XIAF), which neutralizes the anticaspase activity of the apoptosis inhibitor XIAP (Xlinked inhibitor of apoptosis). The TNFrelated apoptosis inducing ligand (TRAIL) is then administered. In colon cancer cell xenografts in mice thus treated, the entire antiapoptotic machinery (XIAP, cIAP2, survivin) was neutralized, and the xenografts were destroyed (268) .
The colon is the battlefield between bacteria and bacteriophages and bacteria and the host (164) . Its genomics/proteomics and epigenetics have gone through a very long evolutionary history. Add the uninvited guest, the human polyomavirus JC, whose T antigen inactivates p53, while it liberates βcatenin for intranuclear entry for interactions with protooncogenes. It is present in 271/766 (35%) of human colon cancers (269) . Now emerges the enterotoxigenic Bacteroides fragilis, as a major contributor to colonic carcinogenesis, according to data emanating from the Johns Hopkins' Cancer Institute (270) .
The B. fragilis enterotoxin cleaves Ecadherin and thus activates the βcatenin/sHH/Wnt cascade. The enterotoxin is neoangiogenic. Colonic mucosal epithelial cells proliferate due to the activation of the STAT/MAPK cascades. Activated NFκB and cIAP2 (Xlinked inhibitor of apoptosis) protect these cells from apoptotic death. The proliferating mucosal cells exude IL8, an activator of NFκB, cyclooxygenase2 and prostaglandin. The bacteroides enterotoxin rearranges the cytoskeleton of the mucosal epithelial cells. In the process, proto oncogenes Kras and cmyc are activated. Further, the human homolog of the drosophila gene 'legless', the B cell lymphoma gene BCL9 becomes activated. This gene is an activator of the βcatenin/Wnt cascade. The major inhibitor of this cascade, the dickkopf1 gene product protein is not produced due to the silencing of the dickkopf1 gene (or its promoter). Some other dickkopf genes (dickkopf3, (70) . In human CpG island methylator genophenotype colon cancer tissue (proven by assaying eight genetic markers), the effect of lymphocytic infiltrates on survival was favorable. The lymphocytes assume Crohnlike, peritumoral, intratumoral periglandular reactions, and tumorinfiltrating patterns (shown in microphotographs). The tumorinfiltrating pattern was associated with significantly improved tumorspecific and overall survival (271) .
Further recent reviews of carcinogenesis in ulcerative colitis explain the genomics and proteomics of that condition, the role of IL13 in the activation of the cell survival STAT pathway (272), but without being able to recognize the ultimate inducing agent(s) (recently reviewed in ref. 62). The highly methylated genes in the inflamed mucosa are the promoter of Ecadherin (CDH1), the transmembrane protein containing epidermal growth factor hyperplastic polyposis (TPEF/HPP), the glial cell linederived neurotrophic factor (GDNF) and the myoblast differentiation genes (273) . Of these genes, CDH1 and HPP exert tumor suppressive functions. This author is impressed by one rare side effect of ipilimumab: 'the hemorrhagic colitis' syndrome. A middleaged male patient D.L. with metastatic melanoma was sent to the NIH/NCI clinics (Bethesda, MD) to receive a then investigational mcab ipilimumab. While he experienced a better than 50% partial regression of his melanoma, he developed 'hemorrhagic enterocolitis' with perforation and died in septic shock. Even though he received corticosteroids to alleviate his 'autoimmune enterocolitis', at postmortem examination (performed by Dr László Karai), the ulcerated intestinal tract, especially the colon, was infiltrated by lymphocytes (unidentified as to clonality) (unpublished data). The inflammatory reactions in ulcerative colitis are of internal autoimmune causation without an external pathogen. Autoimmune diseases of the gastrointestinal tract involve different organs (pancreatitis with ulcerative colitis) (274) . Adenocarcinomas and primary lymphomas of the entire gastrointestinal tract, especially those of the colon with ulcerative colitis, are of autoimmune inflammatory causation (275).
In the nonpolyposis colon cancers, Lynch syndrome, inducer genes are named after their ancestors discovered in yeast cells (276) : postmeiotic segregation (PMS), mutated S and L homolog (MSH, MLH) (277) . In the MSH2associated Lynch syndrome, the epithelial cell adhesion molecule (EpCAM) gene is also deleted (278, 279) . In Lynch syndrome, the oncogenic DNA is repaired mismatched. Mismatched repaired DNA proved to be quite viable in the highly malignant transformed cells. Cancers due to germline gene mutations may not need much inflammatory stimuli. However, the sporadic mucinous colon cancers arising in hypoxic, inflamed microenvironment are commonly rightsided, multifocal and express the PMS. These mucinous colon cancers are infiltrated by lymphocytes, and express PMS2 gene mutations. In a mouse model, the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) decreased peritumoral colitis and NFκB levels (280) .
The intestinal tract suffers from protracted inflammatory processes in ulcerative colitis, Crohn's disease and in non healing rectal fistulasfissures (281283). Polymorphisms of the IL6 genes, epigenetic methylations of the CpG islands of the WTp53 and KRAS2 genes translate into the CIMP (CpG island methylator phenotype) (vide supra). Oxidativeinduced DNA breaks initiate and hypoxiainduced inflammation sustains the growing tumor (284286).
Dietary antioxidants (αtocopherol; βcarotene, the caro tenoid, lycopene) and antiinflammatory agents, aspirin or ibuprofen) are claimed to reduce the rate of inflammatory mutations. Lycopene and tocopherol decreased the rate of p53 mutations; carotens decreased the rate of KRAS mutations. In women, αtocopherol was protective to p53 against CIMP, whereas in men αtocopherol was associated with increased mutation rate in these situations. Only in GG IL6 genotype did high tocopherol levels reduced risks of p53 and KRAS mutations (287).
Prostate cancer. Apart from vertically transferred somatic (acquired), or germ cell mutations (in the minority of cases), this tumor has long been suspected to originate with somatic gene mutations against the background of a chronic inflammation (in the majority of cases). For example, if Mycoplasmataceae are carcinogenic by activating the vav oncogenes (vide supra), could a genitourinary mycoplasma infection be inductive to prostatic adenocarcinoma? Prostatectomy specimens freque ntly yield (35%) Propionibacterium acnes, or corynebacteria, or nanobacteria (288291), but preceding genitourinary mycoplasma infections in the prostate might have been unrecognized. Calcifications in cancerous breast or prostate tissues may indicate reactions of hydroxyapatite and nanobacteria, if nanobacteria as true life forms really existed on Mars and were transferred to Earth by meteorites (292) . As to genetic predisposition and inflammation, the deletion of glutathione Stransferase gene in combination with the histologic picture of 'proliferative inflammatory atrophy' lead to the precancerous intraepithelial neoplasia (293) .
Mice transgenic for vav3 overexpression (vide supra) in the prostate develop NFκB and PI3Kdriven prostate cancers by 3 months of age. These cancer cells also expressed androgen receptor (AR) overactivity. The cancerous glands showed hypervascularity and heavy lymphomononuclear cell infiltrates. Upregulation of HER2 and downregulation of PTEN occurred. When vav3 is activated in the prostate, it may positively interact with the AR, or it may stimulate the growth of prostatic cancer cells independently from AR by activating the PI3K/Akt 'cell survival' pathway (294, 295) . The human vav protooncogene was mapped to 19p1212.2 (137) . Vav3 expression was significantly elevated in androgenindependent human prostate cancer cells. A siRNA complementary to vav3 mRNA inhibited the growth of both androgendependent and independent human prostate cell lines. Molecular inhibitors of PI3K were also effective in inhibiting the growth of vav3 + prostate cancer cells (296) . These authors speak of 'nonbacterial prostatitis' (not to misread as 'nanobacterial'), but do not state if attempts at culturing mycoplasma from the precancerous gland were actually attempted. These authors succeeded in documenting vav3 oncogene activation in 81% of the human breast cancer specimens. Vav activated estrogen receptor expressions (297) . These studies done at Mount Sinai Hospital, New York and at Albert Sabin Way, Cincinnati, OH, are entirely comparable with similar experiments conducted at the University of Miami's Miller School of Medicine (295, 296, 298) . Here, the Rho GTPase guanine nucleotide exchange factor Vav3 was found markedly increased in androgenindependent human prostate cancer cells. The stimulation of AR by Vav3 protein was active in the presence of subnanomolecular androgens. Thus, Vav3 could maintain prostate cancer cell growth in patients receiving androgen deprivation therapy, which is seldom absolutely complete. Intact pleckstrin strands are KSTR amino acid strings (lysine for K, serine for S, threonine for T, arginine for R, in the substrate of leukocyte kinase C of leukocytes and platelets) obligatory to the activity of Vav3 (298) .
A proinflammatory condition in the precarcinomatous/ carcinomatous prostate is consequential to the lipooxygenase product, eicosatetraenoic acid (5oxoETE). H 2 O 2 stimulated the increase of 5oxoETE, nicotinic acid adenodinucleotide phosphate (NADP) and glutathione disulfide. Glutathione reductasedependent generation of NADP was blocked by Nethylmaleimide (NEM). 5oxoETE exerted strong chemo attraction toward granulocytes. Granulocytes further released inflammatory cytokines. Arachidonic acid and calcium ionophore induced selfstimulation of granulocytes by 5oxoETE release, that could be blocked by NEM (299) . Thus, these chemical reactions could induce prostatitis without a pathogen. A macrophage inhibitory cytokine1, member of the TGFfamily prostatederived factor is claimed to inactivate suppressor genes and activate oncogenes (300) .
Two genes held highly suspect in promoting inflammatory carcinogenesis in the prostate were the ribonuclease L (RNASEL) and the MSR1 genes. Further, the Tolllike receptor family genes and the cyclooxygenase gene have been under suspicion. Finally, single nucleotide polymorphism (SNP) of some lympho and cytokine genes was considered to be contributory to inflammatory carcinogenesis of the prostate: IL-1β, IL6, IL8, IL10, and the TNF family genes. SNP in four inflammation pathway genes IL4, IL6; posttranscriptional gene silencing (PTGS2); and STAT3 were most significantly associated with inflammatory carcinogenesis in the prostate. Aggressive prostate cancers were associated with SNP in AKT1, PIK3R1 (phosphoinositide3kinase regulatory subunit 1) and STAT3 genes (301) . (Prostatic intraepithelial neoplasia surrounded by heavy inflammatory infiltrate emerges as one of the most adverse prognostic factors. Rider JC, AACR Press release, Sept 27, 2011).
This most versatile tumor may use nitric oxide (NO) for its cells' survival. The plasma membrane molecule carboxy peptidaseD (CPD) obtains arginine from extracellular sources. Arginine is converted to NO intracellularly. Low doses of testosterone or prolactin upregulate CPD. Through the arginine pathway more NO was generated; these tumor cells gained resistance to apoptotic death (302) . NO suppresses Snail and activates Rafkinase (rat fibrosarcoma) inhibitory protein (RKIP), thus inhibiting EMT of tumor cells (303) (305) . Promoters of EMT are, among others, the loss of tumor suppressor genes p53 and PTEN (306); βmicroglobulins; βcatenin induced by HIF1α; ester12 myristate 13acetate; TGFβ; VEGF; and growth and differentiation factor 9 (GDF9). Estrogen receptor β (ERβ) expression is suppressed in aggressive high Gleason grade prostate cancer cells. The ligand to the ER, 5αandrostane3β17βdiol, maintains the epithelial cell phenotype. Hypoxia and TGFβ suppress ER. Active ER suppresses HIF1α and VEGFA. In the absence of ER activity, VEGFA (neurophilin1) promotes Snail1 in the nucleus, which activates vimentin and all other genes to encode the mesenchymal phenotype (307) . Prostate cancer cells undergoing EMT metastasize. Most circulating tumor cells display EMT phenotype (308a). Hypoxia, TGFβ and VEGF are notoriously active in the inflammasomes. The inflammatory oncoprotein NFκB activates the snail oncogene; the Snail oncoprotein is a major inducer of EMT. The proteasome inhibitor NPI0052 (nonapeptide inhibitor salinosporamide A from marine actinomycete Salinospora tropica), and the NFκB inhibitor DHMQ (same as TMDQ, dimethyl or trimethyl1,2dihydroquinoline) repress Snail and reverse the process of EMT (308b).
MicroRNAs miR143 and miR145 inhibit EMT and bone metastases; however both miRs are downregulated in high Gleason grade tumors and thus are inhibited to act (309) . In aggressive prostate cancers, miR221/222 canceled the mRNAstoprotein translation of p27 (CDKN1B), and p57 (CDKN1C), thus cell growth suppressive cyclindependent kinases were silenced. The miR16 can arrest the cell cycle in G 0 -G 1 by negatively regulating (suppressing) HMGA1 (high mobility group) and CAPRIN (cytoplasmic activation/proliferationassociated protein) genes (310) . 'The oncogene from hell', cmyc → cMYC, can be silenced by miR145, except that miR145 is rendered nonfunctional in aggressive tumors. Some cMYC supportive miRs (miR363, miR92a, miR20b, and miR18b) are upregulated. Three genes upregulated in aggressive prostate cancers (Gleason >8) are CCNA2 (cyclinA2), CDCA5 (cell division cycleassociated) and KIF23 (kinesin family, for rolling movement of the cell nucleus). The two miRs (miR145 and miR3313p) negatively regulating these genes normally, are silenced. When ectopically reexpressed in prostate cancer cell lines, these two miRs exerted growth inhibitory effects (vide infra) (311).
The TMPRSS2ERG gene fusion at locus 21q22 takes place early in prostate cancer cells (transmembrane protease serine 2; etsrelated gene; ets E26 avian erythroblastosis retrovirally acquired cellulartoviral oncogene: cets → vets) (312) . Androgensignaling brings these two genes into proximity, thus inducing their fusion (313) . Altogether, the untranslated 5'UTR region of gene TMPRSS2 (21q22) may fuse with ERG (21q22), ETV1 (7p21), SLC45A3 9 (solute carrier gene) and with HERVK, the human endogenous retrovirus gene, that in extravillous cytotrophoblasts exerts immunosuppressive properties in the defense of the fetus (314, 315) (318) .
Another retroviral genomic sequences (and mature virions, in this case) had allegedly existed in some human prostate cancer cells, both in the stroma and in the tumor cells. This is the xenotropic murine leukemia virusrelated gammaretrovirus (XMRV). The chain of events is such, that TNFα activates NFκB, which activates XMRV. Herpesviruses are known to activate retroviruses (reviewed in ref. 108 ) and in the human prostate EBV latent membrane protein1 (vide infra) also activates XMRV. The p65/RelA (reticuloendothelial) component of NFκB attaches to two sites κB1 and κB2 in the UT3 region of the long terminal repeat of XMRV. The wildtype XMRV replicates in human prostate carcinoma cell lines, in a Burkitt's lymphoma cell line, and in an EBVimmortalized cell line (319) . However, strong new evidence indicates that human prostate cancer xenografts passaged in nude mice picked up two murine proviruses (PreXMRV1 and 2) which recombined to produce replicating XMRV retroviral particles (320) . Picking up murine endogenous retroviruses by human tumor xenografts was observed before (321) . The role of XMRV in inflammation induced human oncogenesis, or in chronic fatigue syndrome, appears to have been negated (320, 322) . Under these circumstances, it remains a tantalizing puzzle how positive results of viral isolations and serological evidence of human infection with the XMRV could possibly be reported. (High risk 'lethal prostate cancers' xenografted in immunosuppressed mice revealed the well known mutations of the TP53 gene and large numbers of highly individual nongermline somatic mutations, 'hypermutations', in DLK2, δlike homolog, GPC6, glypican6, and SDF4, stromal cellderived factor 4, genes; androgen suppressionresistance occurred in Wnt mutated tumors. The individual mutations continued to evolve in the xenografts. Finally, the B cellspecific Moloney mouse leukemia sarcoma viral genome's insertion site BMI1 in the human genome remains a point of interest, inasmuch as this site is involved in the activity of stem cells with (or without) the oncogenic activities of the Sox oncoprotein (SRYrelated high mobility box family transcription factor; sexdetermining region in Y chromosome, vide infra). The BMI1 protein is a transcriptional repressor of the polycomb group gene family.
The immunoreactivity of the BMI protein is in the cytoplasm, where it acts as a negative regulator of the cell cycle (Ink4a/ Arf, inhibitor cyclindependent kinase 4; alternative reading frame), thus cell proliferation. BMI1 is active in stem cells and in several tumors, including gastric and prostatic adenocarcinomas (323, 324) .
Both stromal and malignant epithelial cells in the prostate gland express keratinocyte growth factor, also known as fibroblast growth factor7 (KGF, FGF) and its receptor (KGFR). KGF exerts antiapoptotic (by activating Bcl2 and Bcl XL ) and cell proliferation promotional activities (by activating the Akt or MAPK pathways) (325,326ab) . While KGF induces differentiation into epithelial basal cells, it promotes AR expression (327) . The LNCaP human prostate cancer cell line does not express KGF, but its exposure to external KGF promotes its growth; this is antagonized by flutamide or activin A or vitamin D3 analogs V and BXL628, Université Libre de Bruxelles (328ab330). AR is readily activated in prostate cancer cells by IGF, EGF, and KGF (331) . Several human established prostate cell lines exhibited malignant growth without expressing KGF/KGFR (332), but high Gleason grade and metastatic tumor cells were KGF and/ or KGFRpositive (333) . Benign prostatic hyperplastic cells were negative, but 65% of human prostate cancer tumors were positive for KGF expression, especially in their hormoneinsensitive stages (334) . From these data, it appears that in benign prostatic hyperplasia, whether chronically infected or not, there is very little if any KGF activity, whereas the appearance of KGF activity signifies advanced and probably hormoneresistant disease. The rare paraneoplastic syndrome, bilateral palmar hyperkeratosis with prostate cancer (335) could be an adverse prognostic sign, especially if persists during therapy.
The WW (double tryptophane) domain contains oxidoreductase. The WWOX tumor suppressor gene is best understood in its relation to Tax oncoprotein of the human T cell leukemia virus, HTLVI, and osteosarcomagenesis. While the HTLVI Tax oncoprotein activates the NFκB pathways, WWOX inhibits the HTLVI/Tax/NFκB pathway (336) . In osteosarcomagenesis, WWOX is frequently absent (silenced; mutated). Active WWOX neutralizes the RUNX2 oncoprotein (runt box transcription factor) (337, 338) . Transduced adenoviral and lentiviral vectors are available for attempts at correcting WWOX deficiency. Tested in xenografted human breast cancer cells, WWOX was either reinstated through the adenoviral vector, or reactivated by the demethylating agent 5azadeoxycytidine. Active WWOX inhibited tumor cell growth (339) . Naturaly, WWOX is activated by its ligand PPXY (P = proline, Y = tyrosine, X = any amino acid, W = tryptophane) (340) . WWOX is suppressed in adenocarcinomas other than that of the breast (osteosarcoma, colon cancer, small cell carcinoma of the lung, prostate cancer) (336, 337, 341343) . In small cell carcinoma, it is the BmI1 protein (vide supra) that suppresses WWOX (342) . In prostate cancer, active WWOX not only suppressed tumor growth, but actually induced apoptotic deaths of tumor cells, but in actively growing tumors WWOX is silenced (344) . Since WWOX suppresses HER2/neu + breast cancer cells, it was tested against prostate cancer cells expressing ErbB2, equivalent of HER2/neu. The transcription factor Ap2y activates the Erb2/neu promoter. When ErbB2 is active in prostate cancer, it enhances AR expression and promotes hormoneindependent growth (343) . The tumor cells either function on minuscule amounts of testosterone, or activate their own testosterone production, the ligand for an autocrine loop (AR). The tumor cell carries out the conversion of adrenal androgens into testosterone and dihydrotestosterone and is able to synthesize androgens from cholesterol; these reactions are enhanced by insulin (344, 345) . These androgens as ligands bind the AR in an autocrine circuitry. Cytochrome enzymes P (CYP) are active in this conversion. The CYP enzymes can be antagonized by abiraterone, but they can gain abirateroneresistance (344) .
The Sprouty 1 (Spry1) gene product protein is a tyrosine kinase receptor inhibitor for the fibroblast growth factor (keratinocyte growth factor, vide supra). Prostate cancer cells downregulate Spry1 both by hypermethylation of its DNA, or by silencing its mRNA by targeting it at its 3'UTR region with microRNA21 (345) . The high cysteinerich protein gene (HPCX) encoded from locus Xq27q28 is considered to be a susceptibility gene in hereditary prostate cancer. It is closely associated with genes SPANX (sperm protein associated with nucleus) and MAGEC1 (melanoma antigen gene protein). The SPANX genes exhibit frequent gene deletions, duplications, homologybased sequence transfers and recombinations. The MAGEC1 gene's mRNA offers 12 target sites to miRNAs. Gene MAGE11 resides at Xq28; its protein product belongs to the 'cancertestis antigen family'; it increases the transcriptional activity of the AR. AR is mapped to Xq1112 (347350a). The ectopically expressed super elongation complex gene SEC23A reduced the growth rate of human prostate cancer cell lines without inducing apoptosis. When its mRNA was targeted by microRNAs miR200c and/or miR375, this inhibitory effect was abolished (351) . There appeared a report on genes in the prostate, which are activated by inflammatory events (301) . Of the genes reviewed here, only SPANX appears to be labile and versatile enough to be upregulated by an inflammatory process. The most recent assessment lists those genes that foretell aggressive disease, relapses and prostate cancerrelated deaths. These genes are LEPR (the leptin receptor gene), CRY (the mammalian clock cryptochrome gene), RNASEL (the ribonuclease L gene; latent endoribonuclease, proapoptotic unless suffered gene polymorphism), the IL4gene, and the ARVCF (armadillo repeat protein deleted in velocardiofacial syndrome gene, δ catenin genes, neurojungin, plakophilin, plakoglobin genes) (352) . Except for IL4, the reactions of these genes to inflammatory signals is not well defined at all. The ARVCF gene family is best understood in the context of the metazoan evolution of the catenin gene family (353) . The epigenomics of prostate cancer associated genes (methylation and deacetylation) (354) , and the relationship of genederived mRNAs as targets for microRNAS reveals extraordinary complexity. MiRNA141 levels correlated with those of PSA, lactic dehydrogenase, and circulating tumor cells during the clinical course of prostatic carcinoma (355) . The miRNA200c is activated by oxidative stress (in the inflammasome); by inhibiting oncogene ZEB, it is more of a tumor suppressor gene (356) ; so it is, when it reduces adenocarcinoma formation in Barrett's esophagus (vide supra), or suppresses squamous carcinoma cells in the head and neck region (85, 357) ; but by reducing tumor suppressor Sec23A protein levels, miRNA200c becomes a promoter of prostate cancer cell proliferation (350a). In comparison, miR203 is expressed high in normal prostatic tissues, but it is downregulated in cancerous tissues. In bone metastatic prostate cancer cell lines, miR203 is active in inducing the reversal, the mesenchymal to epithelial reaction (350b).
The Sox (vide supra) family genes are highly upregulated in pluripotent embryonic stem cells to maintain clonogenicity, self renewal and pluripotency, therefore they are active in fetal life. Sox9 is expressed in intestinal crypts and hair follicles (sites of high cellular activities). Stem cells in the basal epithelium of the healthy prostate express Sox9. The sHH, Wnt/βcatenin pathway regulates Sox9. Sox9 is highly expressed in hormonerefractory prostate cancer cells. The Sox9 mRNA can be neutralized by shRNA (358) . The single exon sox2 gene is embedded within a long noncoding RNA at 3q26.327, and exists also in an overlapping transcript: Sox2ot. The sox2ot → SOX2OT is transcribed from a highly conserved element. The ncRNA exercises regulatory function over the expression of the sox2 genes. In active sox2 gene, lysine (K) 4 of histone 3 is trimethylated (H3K4me3); in inactive sox2 gene lysine 27 of histone 3 is trimethylated (H3K27me3) (359) .
In fetal life, Sox is an inducer of ectoderm and neurogenesis. It is downregulated (silenced) upon differentiation. Sox2 undergoes amplifications and mutations, for example in squamous cell carcinomas of mucous membranes of the head and neck and esophagus (82) . Upregulated Sox2 with or without Sox4, Nanog, Oc4, BMI1, and Myc induces adenocarcinomas of breast, endometrium, and prostate (360363). In the prostatic adenocarcinoma stem cells, Sox2 with Nanog, Oct4, Myc, Ras, Klf4 (Krüppellike family transcription factor, from drosophila), Oskar (drosophila oocyte) coexist and coact. Sox is a major contributor to the grade of malignancy: with upregulated CD44 and PSA; apoptosis resistance (without high Bcl2, but with downregulation of Ca 2+ entry), high Ki67 (K index nuclear protein for cell divisions), high Gleason score (8910), and easy transplantability as xenografts. The Sox2 protein was expressed both in the cytoplasm and in the nucleus of the cancer cells. These cancer cells proliferated at an accelerated rate. These cells resisted apoptosisinduction by thapsigargin and cisplatin. In some prostate cancer cells doxycycline induced shRNA release. In mice reeeiving doxycyclin in their drinking water, SOX2 + tumor xenograft grew very slowly (363). Sox2 being the major contributor to all these, when its mRNA is neutralized by a complementary short hairpin shRNA, there is a complete reversal of all malignant scores close to normal: drop of Sox protein, restored apoptosis susceptibility, decreased Ki67 due to a standstill of cell proliferation, drop of Gleason score, and loss of growth potential in xenografts (363) .
Prostate cancer bone metastases appear 'blastic' (osteoblastic), but osteoclastic bone lytic activity is substantial. The runtrelated transcription factor RUNX family proteins (RUNX2, pivotal in osteogenesis) in heterodimers with the Cbfβ protein (Crepeat binding factor; core binding factor) are overexpressed in those prostate cancer cells that metastasized to the bone. These cells have already undergone EMT (364, 365) . However, when an α v integrin antagonist rearranged the tumor cell surface, Ecadherin expression went up and vimentin expression went down, forcing the cell to present itself with less mesenchymal and more epithelial phenotype, thus with reduced locomotion and metastatic spread (366) . The RUNX complex continued to exert prometastatic acts. The DNA proviruses of mouse leukemia retroviruses readily integrated into the runx2 locus (367) . Regulatory Treg cells maintain Fox3 expression through the protective effect of RUNX/cbf complexes on the Fox3 mRNA (368) . The RUNX/cbf complex suppresses the IL4 silencer gene Il4, and thus releases IL4 production (369) . While RUNX maintains Treg and IL4 levels, when antiRUNX targeted therapy becomes available for the treatment of bone metastases by RUNX suppression, IL4 levels and the supply of Treg cells may drop. Tumor cells notoriously utilize IL4 (toleranceinduction) and Treg cells (immune T cell elimination), thus RUNX inhibition may result in some immunological benefits as well. The mcab denosumab is directed at the ligand of RANK, the activator receptor of NFκB; it inhibits bone resorption by osteoclasts (370) . The standard osteoclast inhibitors remain the zoledronic acid preparations.
The oncogenic DNA of high grade prostate cancer cells is endowed with a great deal of biologicalhormonal, radio and chemotherapy resistance. The Dendreon DC vaccine sipuleucel (Provenge), while immunizing against prostatic acid phosphatase, an antigen of minor significance; it barely prolongs life. The PROSTVACVF (Bavarian Nordic) contains a poxvirus (vaccinia and fowlpox virus) expressing PSA with immunostimulatory molecules with or without GMCSF. The PSATRICOM induces powerful immune responses, but as yet without significant clinical benefits (371, 372) .
Oncolytic viral therapy induces stabilization of disease, minor and partial responses (especially by intratumoral injection, that is, into the prostate) and only occasionally complete responses (usually of short duration). Clinically meaningful durable remissions would occur if antiviral immune reactions of the host could be suppressed, or bypassed by using serially and sequentially alternating different oncolytic viruses (164) . Naturally oncolytic (Newcastle disease virus, attenuated poxviruses, reovirus), or genetically engineered oncolytic viruses (adenoviruses, herpesviruses, vesicular stomatitis virus, measles virus, etc.) are available in clinical trials (373389).
Among others, the special ATrich sequencebinding gene product proteins (Satb1, 2) regulate gene expressions in embryonic stem cells. Nanog is a major determinant of stem cell gene expressions. Nanog low stem cells lose their pluripotency to differentiation into somatic cells. Nanog high stem cells may selfrenew, but remain undifferentiated. Low Satb1 protein levels favor the rise of Nanog high stem cells. Satb2 acts by downregulating Satb1. Both Satb1 and 2 proteins actually bind 5'flanking sequence of the Nanog gene. Further, in action, the Satb1 and 2 proteins form homo and heterodimers. Thus, the balance of Satb1/Satb2 directs Nanog in the stem cell toward differentiation, versus the stem cell keeping its pluripoteny persistently (390) . The persistence of pluripotency renders the stem cell conducive to malignant transformation. The transcription factor FoxP3 suppresses the Satb gene in breast and prostate cancer cells; its effect is regulated by miR7 and miR155 (391) . This system is deleted in cancer cells, and is awaiting for its reinsertion by a viral vector. However, the Satb1 mRNAs can be destroyed by a small hairpin RNA. The uniquely prostate cancer specific gene's DD3 (differential display code 3) presence in prostate cancer (DDR3/PCA3) could regulate as a promoter the expression of the shRNA (392, 393 ). An oncolytic adenovirus was constructed to express the gene of SATB1shRNA under the DD3 promoter regulation. This adenoviral vector expressed the antiSatb1 shRNA in prostate cancer cells (cultured in vitro) and was cytopathic to the tumor cells (394) .
The genomic complexity of prostate cancers is extraordinary. While seven genetic patterns have been fairly well sequenced (395) , many more remain still unrecognized. In addition to the well known androgenic pathway, prostate cancer cells over express EGFR, IGFR and prolactin receptors (396399). The appearance of periostin (and tenascin) exclusively in the tumor stroma indicates that they are tumorinduced and as such they should be targeted for therapy (400) .
However, this tumor is not targeted as yet with individualized gene therapy. The primary tumor is treated with the 'fits all' radical prostatectomy, or high dose linear accelerator external beam, and brachyradiotherapy with or without androgen deprivation therapy. The 'Beaumont regimen' revealed that in high risk disease (Gleason >8) apparently still confined to the gland (always questionable), hormonal therapy (noncurative, palliative) delaying high dose radiotherapy was of disadvantage ('detrimental') (401403). This is known since 2007, yet androgendeprivation is still recommended to precede radiotherapy. Unless leuprolide and/or bicalutamide induce tumor cell apoptotic deaths (other than promoting the 'metabolic syndrome' of the patient), the tumor cells arrested in G 0 -G 1 survive the radiotherapy (402) . These are the metabolically active, but rendered irreversibly stagnant (not replicating), 'senescent' tumor cells. This is the situation in which ARnegative neuroectodermal prostate cancer cells may arise (without producing PSA).
The best results for high risk disease would appear to be the immediate high dose interstitial radiotherapy (iridium Ir192 source brachytherapy within the gland and its immediate periphery), preceding the external beam intensitymodulated radiotherapy (IMRT). External beam radiotherapy may induce late carcinogenesis (adenocarcinomas, sarcomas) in the pelvis, and brachytherapy in the prostatic urethra (404, 405) . These tumors probably arise from radiationinduced genemutated cells escaping apoptotic death, but without inflammatory etiology. The predicted incidence of radiotherapyinduced tumors is as high as 1/250 at 5 years, and 1/70 at 10 years (405) .
For metastatic disease, no curative treatment is available, but various cytotoxic chemo, or targeted therapeutic regimens with alternating androgen suppression prolong life. Epigenetic interventions (cancer suppressor gene demethylations or histone reacetylations) hold promise bordering the spectacular, for the restoration of cancer suppressor genes and for the suppression of oncogenes (354, 406) . For the promise of targeted therapy, abiraterone inhibiting the cytochrome enzyme CYP17A1, and the src family kinaseinhibitor, dasatinib, are the examples (407409). Dasatinib is a widespectrum oncogenic kinase inhibitor, acting against the breakpoint/Abelson fusion oncoprotein (BCR/ABL), plateletderived growth factor receptor (PDGFR) and cKIT (kinase target). However, the sequentially and serially mutated oncogenic DNA switches from those suppressed to several new (more than 3) oncoproteindriven pathways.
For the promise of improved immunotherapy, ipilimumab releases autoimmune reactions against cellular targets masquerading as 'self' and as such, it could induce durable remissions in cases of prostatic carcinoma (407, 409) . Subclasses of cytotoxic/cytolytic lymphocytes are able to recognize and attack transforming stem cells. In order to attack prostate stem cell antigenexpressing senescent prostate cancer cells, the T cell receptor could be redirected by bispecific antibodies (410, 411 (412) . The preventive value of dutasteride is in doubt: indeed it has utterly failed to prevent high grade disease. These data explain the increased attention inflammationinduced prostate cancer, frequent, most versatile, and devastating, received in this article.
Endometrial adenocarcinoma. The menstrual cycles were recognized to be inflammatory processes imitating wound healing and inviting the outpour of inflammatory cells (leukocytes, macrophages, NK cells). Even in the menopausal stage, the endometrium is receiving an influx of estrogens without the counterbalance of progesterone; androgen levels may rise. Carcinogenesis in the endometrium may occur both by the intrinsic (cancer is initiated first and then is supported by inflammatory cytokines), or by the extrinsic (chronic or periodical inflammatory processes induce carcinogenesis) pathways. Inactivation of PTEN and consequential activation of the PI3K, and Akt 'cell survival' pathways follows. Cytoplasmic NFκB is liberated to transfer into the nucleus, where it activates a series of inflammatory genes. Chemokine and cytokine showers imbue the tissues. The first gene to undergo point mutation is the Kras (Werner Kirsten's Moloney virusinduced rat sarcoma). The transforming tissues exude prostaglandins and cyclooxygenases. Irreversible malignant proliferation of the endometrium takes place (413, 414) .
The Sox4 oncogene at 6p22 encodes the Wnt/sHH oncogene cascade with Notch and TGFβ signaling. Sox4 is under the suppressive control of the noncoding small miRNA1292. In cancerous endometrium the CpG islands of miRNA1292 are hypermethylated and thus silenced. In response, the Sox4 oncoprotein is upregulated. Patients with hypermethylated miRNA1292 experience poor prognosis and short life expectancy. DNA demethylation (for example, with 2'deoxy 5azacytidine) and histone reacetylation (for example, with the deacetylase inhibitor trichostatin) with resulting restoration of miRNA1292 activity promptly stabilize the course of their disease. Sox4 oncoprotein levels drop; cancer cell proliferation falls to a standstill. Patients with stable disease or actual remission experience prolonged survival (361, 362) .
Melanoma. Ultraviolet light (UV irradiation) induced acquired somatic mutations against the background of UV lightinduced subcutaneous inflammation induce this tumor. The inflammatory mechanisms, if any, that induce visceral, or uveal, melanomas, are unknown. Oncogene Braf (rat fibrosarcoma) is the most common mutation encoding a serinethreonine oncoprotein kinase. This oncoprotein kinase induces abnormalities of the mitotic spindles with aneuploidy in the melanocytes (415) . This author repeatedly reviewed his experience with this tumor, both at the basic science level and in the practice of medical oncology (416, 417) . Patients with melanoma express weak tumorspecific immune reactions in addition to the 'nonspecific inflammatory background'. In past decades, Bacille CalmetteGuerin (BCG) was widely used to stimulate the antimelanomaspecifc immune reactions (418) . Some human melanoma cells activate an endogenous retrovirus, whose role in the etiology of the disease, and in the induction, or suppression, of host immunity remain unresolved (419421).
As to premolecular medicine era immunotherapy, Newcastle disease virus, or influenza A virusoncolysates cancelled or retarded the appearance of metastases after surgical resections of metastatic lymph nodes in stage III disease; in stage IV disease significant prolongation of life was observed in not prospectively randomized patients treated with viral oncolysates (164, 422, 423) . However, overvaccination could be detrimental. Was this due to chronic inflammatory reactions, or overstimulation of leukocytes and macrophages by GMCSF? Eggermont analyzed the problem in his superb editorial (424). Patients with metastatic melanoma eliminate the Th1type internal immunological environment and replace it with the actively tumortolerant Th2type setting (425) . Through the expression of the ICOSL/B7H ligand (inducible T cell costimulatory ligand) by melanoma cells, the host generates large tumor protective Treg cell populations (426) .
The broken chromosomes 1 and 10 undergo mismatched fusion encoding the Fas receptor from 10q2326 on the cell surface, while the cytoplasmic tail is the granulocyte colony stimulating factor encoded from 1p3234. Capturing the Fas ligand (FasL → FasR) induces mitoses of these melanoma cells (Horvath JC, et al, Proc 89th Annual Meeting American Association Cancer Research, New Orleans, LA, 39: 584, abs. 3971, 1998) (427) . Glioblastoma cells utilize the FasL → FasR pathway for their divisions (vide supra) (154) . The malignant cell DNA can use chromosomal breaks and fusions to its own advantage. The malignant cell DNA enlists microRNAs for its propulsion; in melanoma, the miRs30b/30d silence the intercellular communication enzyme NacetylαDgalactosamine polypeptide or Nacetyl galactosamine transferase (GALNT7) and induce the lymphokine IL10 for promoting tumor cell spread in an immunologically tolerant microenvironment (428) .
The mcab ipilimumab and tremelimumab, and the mutated BRAF oncoprotein inhibitor vemurafenib lead the proceedings toward the possible cure of metastatic melanoma.
Sarcoma. The classical tumor with possible inflammatory etiology is the malignant fibrous histiocytoma (429431). Under the inquiry 'malignant fibrous histiocytoma' PubMed lists several examples of this tumor occurring in a lumbar abscess, in the retroperitoneum, in the thymus, in the kidney, in the spermatic cord, etc. HIF promotes the inflammatory process. In the chronic inflammasome, reactive oxygen and nitrogen (Nsynthase, iNOS) species induce DNA strand mutagenesis. A mutagenic product is 8nitroguanine. Coexpression of 8nitroguanine in the nuclei and HIF1α in the cytoplasm of the targeted cell resulted in NFκBdriven sarcomagenesis with adverse prognosis (432) .
Inflammatory lymphocytes reactive to sarcoma cells usually represent complex clones of lymphoid elements. Autologous small round immune T cells and autologous and allogeneic large granular lymphocytes (recognized as NK cells) react to sarcoma cells exploring the target in emperipolesis and either practicing tolerance, or launching a cytolytic attack. Cytotoxicity is expressed either (or both) as cytoplasmic lysis, or 'nuclear clumping', a morphological sign of apoptosis (433) . In a desmoplastic small tumor cell sarcoma, talcuminduced reactive macrophages attacked tumor cells in the pleural cavity (430) .
An established human chondrosarcoma cell line was observed to undergo a slow process of differentiation in vitro. The chondrosarcoma cell line was in advanced passages (over 30 transfers in the 5th year of its establishment), thus considered to be free of any healthy stromal cells, including fibroblasts. To the 33rd passage population of the tumor cell line, small compact, and large granular buffy coatderived lymphocytes (T cells and NK cells) of a healthy donor (JGS) were added. The large often polyploid tumor cells were explored by the donor lymphocytes (in emperipolesis), but suffered very rare incidence of cytolysis or 'nuclear clumping'. Dividing tumor cells gradually yielded elongated fibroblastlike cells in their progeny with single round nuclei without aneuploidy. These cells eventually showed signs of senescence (documented in serial microphotography). The laboratory was experienced in punctually marking and observing cultures with a very good record of avoidance of mixups or crosscontaminations (321, 434) . The unexplained (and held doubtful) 'spontaneous' differentiation of a chondrosarcoma cell line can now be explained by the reaction of PPARγ uniting with their ligands (435) . The artificial ligands of the system (the glitazones, indomethacin) are known, but if lymphocytes could deliver the natural ligands, that has not as yet been explored. If found, a balance of sarcomagenesis in the inflammasomes could be envisioned: the activation of oncogenes counterbalanced by redifferentiation of the transforming cells through ligand activation of their PPARγ receptors. However, the PPARδ pathway (not to be mistaken for the PARP pathway) appeared to be tumorpromoting in adenocarcinomas (vide supra). A chain of events were recognized following the growth arrest of chondrosarcoma chondrocytes by FGF beginning with the dephosphorylation of the RB protein p107, and repression of the E2F genes (436) .
Retrovirally induced sarcomas dominate in the animal world from fish up to simian hosts (429) , but human sarcomas appear as an outstanding exception. Even when retroviral particles are visualized in a human sarcoma, these have not as yet been isolated and identified (431) . It is not clear at all how human sarcomas may be induced by inflammatory reactions, and how inflammatory cells (cytolytic lymphocytes) are actually mobilized to attack them (433) . One can envision inflammasomes generating sarcomas. However even the most scholarly reviews of inflammasomes abstain from such suggestion (437) . Sarcomagenesis in the inflammasome: is it overlooked or is it not happening?
Instead of the expected sarcomagenic retroviruses, two human sarcomas harbor herpesviruses: in multifocal leiomyosarcoma of children EBV, and in all forms of Kaposi's sarcoma, the human herpesvirus8 (HHV8, KSHV) prevail. However, both herpesviruses may activate, or coexist with, endoge nous retroviruses (108, 433) . Herpesvirally induced sarcomas (Kaposi's sarcoma; EBVinduced leiomyosarcoma), evoke their own virusspecific immune reactions (vide infra). Weather these immune reactions are defensive against, or promotional to, these tumors, will be best settled, if both directions are recognized to coexist (vide infra).
Concluding remarks. It was in 1972, when Ruckdeschel et al described their clinical observation on postoperative empyemas reducing relapses of surgically removed lung cancers (438a). A decade later, postoperative intrapleural administration of BCG not only failed to inhibit, but it possibly enhanced, recurrent tumor growths of lung cancer (438b). Nowadays, inflammation is named in the pathogenesis of lung cancer (439,440) and we construct immunotherapy for lung cancer 'from inflammation to vaccination' (441) .
In the 1970's, the reorganized and lavishly supported NIH/ NCI for the Conquest of Cancer issued contracts and grants for the 'nonspecific immunostimulation of patients with leukemias and solid tumor cancers'. It would be interesting to find out if corynebacteria (C. parvum) actually promoted tumor growth. BCG did better: it induced partial regression of some tumors (melanoma, transitional cell carcinoma of the urinary bladder). It became a vogue and a bandwagon to show 510% improvements of chemotherapy results, when BCG was added in the case of practically every tumor; it was then 'the state of art' therapeutical intervention. Yet it has been almost completely abandoned. There was a balance to be found between oncogenic and oncosuppressive immune reactions. The oncogenic inflammatory reactions were not immediately recognized or simply overlooked, and the oncosuppressive immune reactions were overestimated.
At that time (the 1960's), the NIH/NCI steadfastly withheld funding for a 'tumorspecific' immunotherapy protocol (viral oncolysates against melanoma and sarcoma) with or without chemotherapy. Grant applications for viral oncolysate vaccine therapy with chemotherapy combination were rejected as 'mutually exclusive and useless'. However, in the last decade over a dozen clinical trials prove that tumorspecific immunotherapy is additive or even synergistic with chemotheapy, as if chemotherapy inhibited the tumorpromoting inflammatory reactions, and opened up an avenue for the immunotherapy to target the tumor: 'Evidence accumulating in support of cancer vaccines combined with chemotherapy' (442) .
Considering the impressive documentation of inflammatory carcinogenesis, the induction of any new inflammatory reaction (oncolytic viruses, vaccines) into a tumorbearing host should be carefully balanced. Oncolytic viruses and vaccines may work best when combined with a moderate chemotherapy regimen (reducing the tumor load and controlling the oncogenic inflammatory reactions). The newly induced inflammatory reaction of a vaccine or an oncolytic virus should be very specific and forcefully directed against its target; it should be reinforced by chemocytokines and microRNAs with the proven reputation to be proapoptotic and anticarcinogenic.
Pathogens with potentially oncogenic genomic sequences
Viral I. Kaposi's sarcoma cell nuclei are loaded with immature HHV8 particles and frequently release an endogenous retrovirus (similar to, but not identical with, human T cell leukemia virus, HTLVI) (Fig. 4 : if printed in a diminutive size, please view under a magnifying glass).
KSassociated herpesvirus (KSHV, HHV8) reprograms vascular endothelial cells into lymphoendothelial cells (KS cells). The virus infects B lymphocytes and turns them into plasmablasts. Occasionally tonsillary T lymphocytes are also infected. KS cells express the cKit (kinase tyrosin) receptor. The major viral oncoprotein is the G proteincoupled receptor (guanyl nucleotidedependent protein). Open reading frame K12 encodes kaposin A accelerating the MAPK and PI3K pathways, and kaposin B producing endothelial cell regulator Prox 1 (after drosophila gene prospero) (443) . The KS cell genome induces antiapoptotic Bcl2, downregulates Rb and p53, induces mTOR and Notch protooncogenes, and releases autocrine, or receives paracrine growth factors: IFNγ, TNFα, IL6 (reviewed in ref. 444) . KSHV induces ubiquitin ligases and HIF1α, thus contributing to the Warburg effect of anaerobiosis (445a). The viral FLICE inhibitory protein FLIP (FADDlike IL-1β converting enzyme, Fas death domain) contributes STAT activation and spindle cell formation. Viral ORF57 encodes vIL6; its mRNA transcript accumulation (TA) and miRNA recognition elements (MRE) stabilize viral and host cell IL6 mRNAs (443,445b) .
The human interferon (IFN) regulatory factorrelated KSHV gene (vIRF3) inhibits types I and II IFN production in effusion lymphoma cells; it inhibits histocompatibility complex class II expression (thus antigenic presentations). In a peculiar way, IFNγ production was also inhibited (whereas IFNγ was shown to be a growth factor for KSHV) (446, 447) .
KS cells release 17 adenylated miRNAs. KS miRK127 and miRK1275p target the 3'UTR of RTA (replication and transcription activator) and the viral immediate early gene, thus maintaining viral latency (448) . The genome of KSHV releases 12 microRNAs (miR) from its LANAassociated intron. These miRs posttranscriptionally regulate host cell gene expressions by silencing the corresponding mRNAs. The translation of the miR of thrombospondin is inhibited; thrombospondin is a strong tumor suppressor and antineoangiogenic factor (449) . The nuclear ribonuclease Droshacleaved hairpin RNA exits the nucleus with exportin5, is processed by cytoplasmic ribonuclease Dicer, is incorporated into the RNAinduced silencing complex and thus is guided to the 3'UTR of the targeted mRNA, which is degraded. These viral 
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miRs have no sequence conservation to metazoan miRs. But the KSHVinduced miRK1211 is homologous to the host lymphoma cellinduced miR155. These miRs regulate the BTB (bric á brac) and CNC (cap'n collar) homology domains, abbreviated as BACH (450453). BACH1 is a negative regulator of transcription recognizing antioxidant response elements within gene promoters. In suppressing BACH1, the membranebound subunit of the amino acid transporter xCT increases, thus intracellular glutathione stores remain full providing protection against oxidative stress. Further, xCT is the cell surface receptor for the entry of KSHV (454) . The Orf63 of KSHV is homologous to the cellular NLR (nucleotide binding and oligomerization, leucinerich repeat), which activates innate immune reactions in the inflammasome. KSHV Orf63 protein blocks the cellular NLR at its initiation (IL1β, caspase1 and IL18), thus the virus escapes the activation of innate immunity and its consequences (455) . Classical preAIDS KS had the reputation to be a tumor afflicting immunosuppressed hosts (immunosuppressed organ transplant recipients). The classical Southern European patients were elderly. Even in the virulent African KS, an immune system exhausted by bacterial, protozoal and helminthic infections was blamed for the acceptance of these tumors. Severe immunosuppression in HIV1infected patients with the acquired immunodeficiency syndrome was thought to render these patients defenseless to these tumors. However, in the most paradoxical way, the recrudescence of virulent KS in these patients after viral inhibitory therapyinduced remission of AIDS with recovery of the immune competence proved that KS could be subject of inflammatory oncogenesis. A long list of references attest to this concept (E.A. Mesri citing articles from Y. Aoki, C. Boshoff, J.L. Douglas, B. Ensoli, R.C. Gallo, P. Monini, L. Pantanowitz, G. Riva, etc.) (456) . To the dissatisfaction of this author, these articles speak in generalities and fail to pinpoint the exact tumorsupporting infectiousimmunological mechanisms. Constituents of the inflammatory infiltrates around the tumors are listed one by one (DCs, several different classes of lymphoid cells including plasma cells, NK cells, monocytes/ macrophages), but without their roles in oncogenesis, or in the defense against it, specified. In patients with KS, immune T cells and cytolytic NK cell are generated, exert cytotoxity to malignantly transformed cells, but eventually fail to control tumor growth (457459). However, there is recovery from KS, that is regressions of these tumor may occur, for example in organ transplant recipients, when the immunosuppressive medication is withdrawn or modified (460462). Immunosuppression with rapamycin exerts also antitumor effects by the inhibition of the mTOR pathway (mammalian target of rapamycin), thus it may reduce posttransplant Kaposi's sarcoma generation with retention of the graft. HHV8/KSHV remains in latency failing to enter its lytic cycle in rapamycintreated viruscarrier cells. Rapamycin specifically inhibits the replication and transcription activator (RTA), the lytic switch protein (463) . + diffuse large B cell lymphoma in the elderly; it is associated with brain lymphomas in patients with AIDS, it is present in multifocal pediatric leiomyosarcomas, and in gastric carcinomas in Japan (reviewed in refs. 62, 443) . In autoimmune diseases (lupus erythematosus, multiple sclerosis), there is an interaction between EBV and latent endogenous retrovirus(es). Herpesviruses trigger the maturation of latent endogenous retroviruses, which appear budding from lymphoid cells, ReedSternberg cells, and even the transformed lymphoendothelial cells of Kaposi's sarcoma (62, 108, 178, 464) .
The EBV genome is present in T cells of angiocentric lymphomas presenting as 'lethal midline granuloma' (465), a pathological entity different from the lethal midline granulomas caused by malignantly transformed NKT cells (466468). In patients with Xlinked lymphoproliferative disease with SAP gene mutation (SLAMassociated adaptor protein containing SH2 domain; SH2, Src homology; SLAM, signaling lymphocyte activation molecule), EBV infections are lifethreatening (469) . It is the tolerogenic, Th2type immunological environment inducer IL10 that activates the expression of EBV's LMP1 in Burkitt's lymphoma and in NK cell lymphomas (470) . After EBV infection in healthy individuals, the viral genome rests in a circular configuration in the epigenome. The cytokines IL4, IL13 and IL21, DNAmethylations and histone acetylations deacetylations control the mode of expression of the latent EBV genome. For the host's health, the most ominous change is the expression of the latent membrane protein (LMP1, 2A, 2B) (471475).
In order to neutralize host cell mRNAs, which are to be translated into defensive inflammatory proteins, the EBV genome generates numerous (may be over 25) microRNAs (EBERs) (474, 475) . The EBV genome BamHIA rightward fragment (BARF) and BamHI (Bacillus amyloliquefaciens endonuclease) fragment H rightward open reading frame (BHRF1) release the viral microRNAs most frequently in the case of type III latency in nasopharyngeal tissues. EBV miRNAs target chemokine CXCl11, inhibit transition from latent to lytic viral replication, and suppress the p53 upregulated mediator of apoptosis (PUMA), and regulate the expression of LMP (476) . The Nterminus of the BARF protein activates Bcl2 and protooncogene cmyc. Soluble BARF protein imitates a CSF and thus is mitogenic; it suppresses IFNα production. Gammaherpesviral miRs are orthologs and interrelated (shared seed sequences) among Marek's disease HV of turkeys, KSHV and others (miR155) (477) .
IL4 and IL13induced STAT pathway elicits EBV's LMP induction (471473). LMP is a protooncogene. EBNA2 and EBNA5, IL10 and IL21 induce LMP expression. The truncated LMP transforms and immortalizes B cells and activates Bcl2, NFκB, STAT1 and JAK3 (janus kinase). LMP suppresses proapoptotic p53 and Bax signals (Bcl2associated X protein). LMP induces miR29b, and thus downregulates TCL1 (T cell leukemia) oncogene (478) . The negative regulation of an oncoprotein by EBV LMP must have some so far unclear biological implications. LMP2A activates PI3K/Akt/mTOR pathways. In a mouse model of Burkitt's lymphoma with cmyc translocation, rapamycin suppressed splenomegaly and tumor metastases (479) . Host snail and twist gene activations lead to epithelialto mesenchymal transition of EBVinfected cells in NP carcinoma. Translocated βcatenin from cytoplasm to nucleus activates protooncogenes (480) . LMP1 increases intranuclear transfer and accumulation of βcatenin (481) . The LMP of EBV activates STAT protein kinase C (PKC) and ERK (extracellular signal regulator kinase) (482) . Malignantly transformed cells operate these very same signaling pathways.
In the EBV granuloma/inflammasome there are lymphoid cells infiltrating (CD8 + CD4 + T cells and CD4 + CD25 + Fox3 + Treg cells, NK cells, B lineage cells depositing immunoglobulins), mast cells, neutrophil and eosinophil leukocytes and inflammatory lymphokines (IL1β, IL3, IL6, IL8) and chemokines (CXCL1, the IL8 analog, CXCL22, CXCL56), further, RANTES and MCP1 (regulated on activation normal T cell expressed secreted; macrophage chemoattractant protein) and NFκB and TNFα lubricate the interstitium. These agents one by one or in unison maintain an inflammatory environment serving the virus and the tumor to the disadvantage of the host (483) .
EBVassociated multifocal smooth muscle tumors occur worldwide and target children. These tumors are now being recognized in Singapore as leiomyosarcomas in EBER + immunosuppressed kidney transplant recipient adults. EBV latency was considered to be type II (vide supra). The tumors persisted and advanced after the discontinuation of the immunosuppressive medication (cyclosporine and prednisone). The tumors activate the mTOR/Akt pathway of oncogenesis. The Ras association domain family gene (RRASSF1A) was methylated (considered to be silenced) and the MGMT gene (methylguanineDNA methyltransferase) was hypomethylated (yet considered to be silenced) in every case. It is known that EBV LMP attacks (suppresses) RASSF1A. The mTOR inhibitor sirolimus (rapamycin) induced remission in a patient with a leiomyosarcoma in the liver. The tumors were chemotherapyresistant. Demethylation of the RASSF1A gene could be attempted, however, demethylators can liberate the latent EBV genome (484) . A lung transplant patient developed EBV + uterine leiomyosarcoma (485) . A retroperitoneal inflammatory leiomyosarcoma was first mistaken for a malignant fibrous histiocytoma (vide supra) (486) . It is not known if this tumor was EBVassociated. May be all leiomyosarcomas should be submitted to the ChangMoore digital transcriptome subtraction technology in search for an epigenetically hidden circular EBV genome (as this technology worked for the recognition of HHV8/KSHV, vide supra).
In activating the ras (Harvey or Kirsten rat sarcoma) protooncogenes gammaherpesviruses can induce a cascade of intracellular events, the most prominent being the preoncogenic PIK3 'cell survival pathway' (487a). Viral III. In the chronically inflamed uterine cervix, the high risk papilloma virus deposits its E6 (to target p53) and E7 (to target RB) oncogenes; after neutralizing these tumor suppressor genes, actual activation of oncogenes follows (487b). High risk human papillomavirus, (HPV16/18), causes squamous cell carcinomas of the uterine cervix, and with or without EBV, is responsible for carcinogenesis in the oral cavity and nasopharynx (487c,488). These are the lymphoepitheliomalike HPVrelated head and neck carcinomas (489, 490) . In North America the incidence of HPV16 + EBV -nasopharyngeal carcinomas are increasing (491) . High risk HPV16 shows up in anal warts (491) and in anal squamous cell carcinomas (493) .
The target cells of the virus are keratinocytes and other epithelial cells. Against the background of nonspecific chronic inflammation (in the uterine cervix, in the nasopharynx, in the anorectum), the HPV16 E6 and E7 oncoproteins heterodimerize with the p53 protein and the RB protein and these complexes are removed by ubiquitination. HPV16's oncogenes E6 and E7 share a common promoter. The complex formation involves the LXCXE (L, leucine; C, cysteine; E, glutamine and X, any amino acid) motif of E7 fitting into a pocket of the RB protein (494496). The virally infected cell loses its major propensity toward apoptosis and cell cycle control. Degradation of the regulator of hTERT, nuclear factor binding box 1 (NFX1), removes hTERT repression (human telomerase reverse trans criptase) and thus immortalizes the infected cell. Normally NFX1 promotes the generation of protein p105, an inhibitor of NFκB (497) . With degraded NFX1, the p105 protein is not generated; consequentially NFκB levels rise. The virus induces centriole overduplication and the infected cells divide with supernumerary mitotic spindles; consequentially, aneuploidy sets in and the chromosomes become missegregated. HPV16 activates the pololike kinase 4 promoter; plk4 mRNAs are overproduced and the cell cycle accelerates its G2 to M progression. Under hypoxic inflammatory conditions, E6 inactivates the human tumor suppressor deubiquitinase gene CYLD (cylindromatosis); this act rescues NFκB for unrestricted activity (498500a). The inflammasome of the uterine cervix is bathed in high levels of the tolerogenic IL10. It is the peripheral blood mononuclear cells that produce IL10; the CpG islands of the proximal promoters for IL10 production in the epithelial cells were silenced by hypermethylation (500b).
There appears to be an abundance of identified and un identified microRNAs released from the genomes of papillomavirusinfected tumor cells and from the viral genome (501) . An outstanding example is miR200a, which downregulates oncogenes ZEB1, 2 and TGFβ (vide supra). These oncogenes work through the Ecadherin/βcatenin pathway in promoting EMT of the tumor cells, thus initiating metastatic spread. Expression of miR200a suppresses tumor metastases (502) .
The oncoprotein E7 downregulates the oncosuppressor and cell differentiation inducer miR203. The target for negative regulation by miR203 is p63, the level of which gradually drops as stem cells differentiate. Viral oncoprotein E5 lowers miR203, and raises p63 levels. The cancer cell proliferation inducer miR146a is active in cervical cancer cells (also active in breast, pancreatic and some prostate cancer cells, as well as in psoriasis). The immunosuppressive miR146a is strongly upregulated in cervical carcinoma cells; miR146a is upregulated by oncoprotein E5. From the point of view of inflammatory carcinogenesis, it is important to observe the suppressor of cytokine signaling proteins, SOCS3: they suppress IL6 and IFN production. Whereas, miR203 targets SOCS3 for negative regulation, thus inducing increased inflammatory responses (503) .
Host immunity can eliminate early lesions of cervical carcinogenesis, but the immunity thus gained may be ineffective in protecting against a newly acquired papillomavirus infection (504) . High grade cervical dysplasia persists with the continuous expression of the HPV16 E7 oncoprotein. This oncoprotein overrides the suppressor activity of p21 cip1 (505 (506) . Mice carriers of lungmetastasizing E7 + tumors could be induced into remissions by immunizing them with intralymph node injections of an E7 vaccine and treating them with a dsRNA TLR3 ligand (507) .
Nitric oxide synthases generate the free radical from Larginine. The bioreactivity of NO consists of the induction of ss and dsDNA breaks and DNA crosslinkages. In the DNA molecule G:C and T:A transversions occur resulting in the formation of the mutagenic 8nitroguanine. The wildtype p53 eliminates damaged cells by inducing their apoptotic death. However, when E6 causes the degradation of p53, and E7 blocked the retinoblastoma protein, the mutated viruscarrier cells survive and replicate. Thus an inflammatory condition with the release of free radicals is cocarcinogenic (508a).
About one third (38%) of the inflammasomes of actinic keratosis and the nonmelanoma skin cancers (basal cell and squamous cell carcinomas) that follow harbor HPV genomic sequences (by PCR assays), but practically none herpesviral (EBV, CMV) sequences (508b).
Viral IV. Hepatitis B and C viruses with or without alcohol and/ or aflatoxin exposure induce hepatocellular carcinoma (HCC), after keeping the liver parenchyma inflamed and becoming cirrhotic for several years (or decades). G1896A and A1762T/ G1764 double mutant HBV induces cirrhosis and HCC. Serum HBV DNA levels may clear to the negative stage of HBeAg and HBsAg. G1776A viral genomic mutations favorably prognosticated the achievement of a negative HBeAg status (509, 510) . The proteomics of infected hepatocytes in patients with hepatitis B surface antigen (SHBs) expression revealed high rate of apoptotic deaths. Apoptosissusceptibility or resistance was regulated by the following genes: glucoseregulated protein 78 kDa (GRP78), heterogenous nuclear ribonucleoprotein H3, Rho GDP (guanine diphosphate) dissociation inhibitor, cystatin B, far upstream elementbinding protein and TNF receptor associated protein 1. The gene GRP78 encoded apoptosisresistance; siRNA treatment silencing this gene resulted in apoptosis susceptibility. Circulating hepatitis B surface antigen (HBsAG) rendered infected hepatocytes susceptible to apoptosis (511) .
The HBV genome is directly oncogenic; it is often compared to the retroviral genome's RNA transcribed into proviral DNA by the viral RT. Like in the case of retroviruses, the HBV genomic DNA also integrates into the host cell's genome. The HBV X gene (Hex) and its oncoprotein eliminate the pro apoptotic p53 protein, activate methyltransferases to silence more tumor suppressor genes, or gene promoters, by hypermethylation and increase telomerase activity. In summation, it is an antiapoptosis and antisenescence agent (512) . HBx activates miR29a, which suppresses PTEN and promotes the migration of transformed liver (hepatocellular carcinoma) cells (513) .
Hepatitis C virus (HCV) enters cells through the integral tight junction protein occludin and its membraneassociated MARVEL domain (MAL proteins, myelin and lymphocytes; MALrelated for vesicle trafficking and membrane link) (514) . MARVELdefective cells were nonpermissive to HCV entry. The HCV envelope proteins E1 and E2 interact with the phospholipid scramblase 1 securing attachment of the viral particles (515) . Only hepatocytes are susceptible to CV entry and its core proteins (Core 3a) interact with host proteins, the heterogenous nuclear ribonucleoprotein H1, nuclear factor 45, and C14 open reading frame 166 (516) . These interactions trigger the preoncogenic pathways in the infected cells. These processes occur against the background of antiviral immune reactions in the liver parenchyma, which include oxidative stress and neo angiogenesis. Generation of iNOS, Cox2, VEGF, PGE2 and activation of the Akt pathway occur. Administration of Core 3a and Cox2 specific siRNAs reduced all these reactions and the size of the viral progenies released (517, 518) . HCV genome encodes p7, a peptide functioning as an ion channel in lipid bilayered membranes. RNA interference (siRNA) inhibits the encoding of HCV envelope proteins E1, 2 and thus reduces intracellular viral replication (519abcd). Chronic HCV infection could culminate into MALT lymphoma with t(14;18) IgH/ Bcl2 translocation (520) .
About 55% of the patients with HCV infection treated with pegylated IFNα and ribavirin can achieve sustained viral remissions depending on the viral genotype and the type of the patients' immune response. Of the lymphocytokine response, steady levels of IL4 (a Th2type inducer) and TNFα (a Th1type inducer) were necessary (521) .
Nrf2, the nuclear factor erythroid2 related factor2 is acti vated in response to oxidative stress in HCVinfected cells. MAPK is the activator. Under these circumstances phosphorylated Akt is also activated. Activated Nrf2 and the 'cell survival pathways' overcome BAD (Bcl2 antagonist of cell death) and prolong the life of HCVinfected cells (522) . In HCVinduced liver cirrhosis and HCC, TGFβ induces EMT resulting in invasion and metastasis by the transformed tumor cells (523) . Notoriously, NFκB protects HCC from apoptotic death. The protein NEMO (NF essential modulator) activates NFκB; if it is switched off, NFκB remains silent, thus HCCs are allowed to die apoptotic death (524) . In patients with advanced precancerous liver cirrhosis, the antiinflammatory agent colchicine prevented malignant transformation: this occurred in Ciudad Mexico in 9% of colchicinetreated patients versus in 29% of untreated patients (525) . Previously, treatment with lamivudine, adefovir, tenofovir protected somewhat patients with hepatitis B from HCC advancement (526) . Now, surgically nonresectable HCC is being treated with sorafenib or sunitinib, or with oncolytic virus therapy, i.e., genetically engineered adeno, herpes, measles, myxo, retrolenti, vaccinia, and vesicular stomatitis viruses (164, 527531) . Sunitinib reduces the number of myeloid suppressor and Treg cells (532) . The mechanisms of viral oncolysis directly targeting cancer cells should override any possible adverse effect on inflammatory carcinogenesis.
Bacterial. Helicobacter pylori (Hp) is the classical bacterial pathogen that induces severe, hostdamaging inflammatory reactions, while depositing its oncogene cagA (cytotoxinassociated gene product protein) in epithelial cells of the gastric mucosa, or in lymphocytes invading the lesions. Its pathogenesis generated an excessive literature that was recently and repeatedly reviewed in ref. 62 . In a brief summary for a very complex issue (by a clinical oncologisthematologistinfectious diseases specialist, who has had the opportunity to diagnose and treat patients with H. pyloriinduced MALT lymphomas): CagA entering lymphocytes and/or gastric mucosal epithelial cells, undergoes phosphorylation, binds Src kinase and src homology domain 2containing tyrosine phosphatase (Rous sarcoma csrc protooncogene) and activates extracellular signalregulated kinase (ERK). The MAPK cascade is activated. In lymphocytes, the antiapoptotic Bcl XL proteins take over. In gastric mucosal cells, H. pylori induces hypermethylation of the CpG dinucleotides, and deacetylation of histone tailes, and methylations of selected lysine and arginine groups of histones in gene promoters. The inactivation of the gene for RUNX3 (533) by CpG island hypermethylation provided apoptosisresistance of the involved cells, mediated by Bcl2 and Bcl XL overriding the proapoptotic BAX and BAK proteins (runtrelated transcription factor, B cell lymphoma extra large, Bcl2associated X protein, Bcl2 antagonist killer) MALT lymphomas are originated in the stomach and elsewhere (534, 535) . Gene translocations characterize MALT lymphoma cells: t(11;18)(q21;q21), t(14;18)(q32;q21) favoring IgH and Bcl2 and the activation and release of NFκB. Hpinfected macrophages release a proliferation inducing ligand (APRIL) to B cell receptors (536538).
The epithelial cells assume goblet cell phenotypes ('intestinal metaplasia'). The cytoplasmic βcatenin translocates to the nucleus, where it is to activate some protooncogenes (539, 540) . Several CpG islands are methylated in a reversible fashion: most of the sites (not all of them) get demethylated after the eradication of Hp (541) . The WWOX tumor suppressor gene (vide supra) is silenced by hypermethylation of its promoter (542) . Overriding cell senescence, CagA induces the guanine exchange factor/cMyc/miRNAp21 waf/cip axis for driving the cell cycle toward uncontrolled proliferation and EMT, tantamount to local invasion and distant metastasis formation (535) . In Germany, a second Hp protein GroEL emerges independently from CagA, as a major contributor to gastric carcinogenesis (543) . Lymphocyte and granulocytemonocytemediated immune reactions are generated, but fail. Reactive oxygen and nitrogen species rise to induce dsDNA breaks. H. pyloristimu lated macrophages in MALT lymphoma release APRIL, the proliferationinducing ligand (537) . Early H. pylori invasion is reversible (with specific antibiotic regimens). In a case, H. pylori infection was disgnosed and was immediately treated, while lymph node biopsy results were not immediately available. Treatment for H. pylori infection resulted in rapid regression of lymphadenopathy. Thereafter the lymph node biopsies revealed Burkitt'slike lymphoma EBVnegative with cMyc rearrangement, but without Bcl2 translocation (544) .
Hungarian clinicians are very interested in those enzyme inhibitors (targeting urease, carbonic anhydrase, γglutamyl transpeptidase, efflux pump inhibitors) that may inhibit the growth of chlarythromycinresistant strains of Hp (545) .
Genitourinary parasites. Schistosoma haematobium induces squamous cell carcinoma of the urinary bladder in Central and North Africa (Burkina Faso; Cameroon; Egypt, Entebbe, at Lake Victoria, Uganda; Msambweni, Kenya; Southwestern Morocco, Lake Malawi, Nyasa/Niassa, Mozambique and Tanzania; Erinia River, Osun, Nigeria; Niger; Lusaka province, Zambia; lakes and Limpopo River, Zimbabwe). The intermediate host is the snail sp Bulinus (especially B. truncates/truncatus). However, it was in Brazil, where the hemocytes of the snail sp Biomphalaria were found to be selfprotective against S. mansoni. The snail hemolyph contains amoebocytes and haemocytes; the haemocytes are granulocytes and hyalinocytes. The granulocytes move on psedopods, phagocytose and encapsulate the parasites (546) . Eli Metchnikov (ИЛЬЯ ИЛЬИЧ МЕЧНИКОВ 1845 1916) observed the phenomenon of phagocytosis in the belly of Daphnia pulex, whose entire genome has just now been sequenced in full. The innate immune faculties of the snail offer better protection against the cercaria (547), than the united innate and adaptive immune faculties of the human host. The snail phagocytes generate nitrite oxide to kill the parasites. In the human host, tumor cell genomics give no clear explanation of the pathognesis. Genomics (including the mt genome) of the parasites revealed the lines of their phylogenesis, but so far gave little information as to their ability of evading the infested host's defenses (548, 549) . However, an extraordinary study on the snails' innate immunity as it is activated against the trematodes, revealed that their thioestercontaining protein (TEP) regulates the phagocytosis and encapsulation of the parasites. The fibrinogenrelated proteins (FREPs) in a specific and variable manner react with polymorphic mucins of the parasites. These reactions are between diversified immune receptors of the host, and antigenic variants of the parasite (550) . In the human host, the tumor suppressor gene p53 may or may not be down regulated, but the antiapoptotic Bcl2 gene is activated (551) . Only the mucinous and signet ring adenocarcinomas expressed intense cMyc (552) . The RB gene was occasionally suppressed; p53 mutations occurred in 57% of the tumors. Ras gene point mutations, EGFR cErb2 amplifications occurred irregularly (553) . The detectable genomic changes (p53, Hras, VEGF) could not be used as prognostic factors as to the outcome of the disease (554) . However, p53 mutation and high Ki67 expression indicated advanced disease and poor prognosis (555) . Human cancer cells, especially those of colon carcinoma, overexpress the highly conserved oncofetal antigens TA1/E16 (tumor associated, embryonic day 16 lymphocyte activating). Protein homologues of these antigens are expressed in schistosoma species (S. mansoni) (556) , and as such, they may act as oncogenes in human cancers.
Pololike kinases (Plk15) encode centrosome spindle formatting proteins in schistosoma and in cancer cells. The patented drug Bl2536 inhibits mitoses in schistosoma and in cancer cells (557) .
Opisthorchis viverrini, and Clonorchis sinensis, the liver flukes, induce cholangiocarcinoma of the bile ducts. In the tumor cells Ski/SnoN oncoproteins are highly overexpressed (SloanKettering Institute). These are avian retrovirusrelated oncoproteins discovered at the SloanKettering Institute, New York. Protooncogene vski was captured by an avian erythroleukemia retrovirus SKIT (cski → vski). The human cski locus maps to 1q2224. Oncoproteins cSki/SnoN (Ski novel protein) are overexpressed in cholangiocarcinoma with or without induction by O. viverrini. SnoN binds the Smad complex and repress TGFβ's inhibitory effect on cell proliferation, thus acting as an oncogene. SnoN binds the promyelocytic leukemia (PML) protein and they thus stabilize p53; the cell undergoes senescence and apoptosis. SnoN acted as an antioncogene (EMBO J 2889). In cholangiocarcinoma cells, the retinoblastoma (Rb) and p16(INK4) proteins are reduced. Cyclin D1, CDK4 and Smad4 are upregulated (inhibitor of CDK4, cyclindependent kinase; mothers against decapentaplegic, from drosophila; decapentaplegic = TGFβ ligand). Oncoprotein cSki suppresses TGFβR, as its direct antagonist. Active TGFβ antagonizes cSki by suppressing its neoangiogenic and metastatic potentials. The negative cMyc regulator tristetrapolin (TTP) is disabled by a CpG site methylation, thus liberating cMyc for the suppression of the antiproliferative effect of TGFβ (558566).
Are the notoriously present latent polyomaviruses JC and BK contributory to carcinogenesis in the GU tract? Extending the question to SV40 simian polyomavirus, that was present in some live attenuated poliomyelitis vaccines, and to the Merkel cell carcinoma polyomavirus, these agents are highly suspect contributors to some rare human neuroectodermal cancers expressing the T oncoprotein and/or integrated viral genomic sequences in the tumor cells' genome. Inflammatory monocytes serve as a reservoir for the Merkel cell polyomavirus (567572).
Mechanisms of inflammatory carcinogenesis
Proteomics. Granuleloaded eosinophil granulocytes are expected to exert complex antitumor effects wihin inflammasomes (vide supra). In Hodgkin's granulomas the eosinophils fail to subdue the ReedSternberg cell (Fig. 2) . The eosinophil granulocytes themselves may succumb to malignant transformation in the form of various hypereosinophilic syndromes including eosinophilic leukemia. The fusion inducing protein/ oncogene includes the plateletderived growth factor receptor α gene (FIP/FDGFR), susceptible to inhibition by imatinib mesylate or dasatinib. Inflammatory defensive cells, be monocytes, granulocytes, lymphoid cells (lymphocytes and NK cells) or mast cells, do readily succumb to malignant transformation. TAMs are often subverted supporters of growth factors to the tumor. Immature dendritic cells (DCs) are often tolerogenic. The presence of CD123 + plasmacytoid DCs in breast cancer tissue is associated with poor prognosis (13) .
Genetic polymorphisms (single nucleotide polymorphisms, SNP) may bring out the unexpected: a defensive immune reaction may be the inducer of malignant tranformation in these individuals. SNP of the TLR4 or some of the 'inflammatory genes' increases the risk of high grade prostate cancers. Proinflammatory IL1 gene cluster polymorphism increases the risk of gastric cancer induction in the H. pyloriinfected organ (vide supra). When TLR4 recognizes LPS endotoxin, it signals through MyD88/IL1 to induce NFκB and the MAPK pathway. Polymorphism of the TLR4 gene may result in defective signaling, lack of defensive reactions and consequentially severe direct tissue damage by the endotoxin (13) .
Of damageassociated molecular pattern (DAMP) molecules, high mobility group proteins A and B emerge (HMGAB), as they are released from necrotic cells. The cognate receptors of HMBAB proteins are the RAGE (receptors for advanced glycation end products, glycation, nonenzymatic glycolyzation), or TLR2, TLR4. These receptors generate NFκB, Eselectins and insulinlike growth factor and/or its receptor, IGFR (selectins are ligands to sialylated cell surface carbohydrates) (13) .
How could defensive inflammatory reactions of a host derailed toward carcinogenesis? The promotion of the HER2/ neu oncogene by Freund's adjuvant settled the issue (573) . Dormant oncogenes are awakened and activated, when the host mobilizes inflammatory reactions. The importance of chronic inflammatory processes in carcinogenesis is best proven by the antioncogenic efficacy of antiinflammatory agents. The most efficient antiinflammatory and oncogenesis inhibitory agents are ethyl pyruvate, nonsteroidal antiinflammatory drugs (acetyl salicylic acid, ibuprofen), prostaglandin and COX2 inhibitors (celecoxib) (13) .
The human nitric oxide synthase gene is upregulated by the Wnt/βcatenin/Tcf4 signaling (T cell factor/lymphoid enhancer factor). TNFα, IL-1β and IFNγ induce nitric oxide expression (hiNOS) by acting on the NOS gene promoter. NFκB is suppressed by βcatenin. The summation of these reactions is a decrease of hiNOS production in colon cancer and hepato cellular cancer cell lines (574) .
Autophagy. Reduced HMG proteins induce mitochondrial superoxide production promoting autophagic cells. Other inducers of autophagy are perifosine (an mTOR inhibitor), and TGFβ (a multifunctional cytokine) (575, 576) . In autophagic cells, induced by autophagy genes, the cell survival pathway PI3K and the proapoptotic beclin (the mammalian ortholog of yeast autophagy gene, atg) compete; Bcl2/Bcl XL antagonize beclin (577) . Autophagic tumor cells may recover as progressive tumors; this can be inhibited by hydroxychloroquine (578) . Autophagy may protect tumor cell during genotoxic and metabolic stress. However, resveratrol and curcumin may induce tumor cell death in autophagy and in mitotic catastrophe (579581). The mitochondrial alternating reading frame, p14 ARF exerts antitumor effects by antagonizing MDM2, thus protecting p53, and suppressing cmyc/MYC. In autophagic cells, p14 ARF removes the Beclin/Bcl XL complex and suppresses tumor cell recovery from autophagy (582) . Inflammatory events in the tumor environment may induce autophagy of tumor cells as a stress adaptation response (583ab).
Autoimmunity. The epigenomics of EBV (474, 584, 585) , and reactivated endogenous retroviruses definitely are major contributors to the etiology of autoimmunity, especially in lupus erythematosus and multiple sclerosis (reviewed in ref. 178, 474, 586) .
While the omnipresent cytoplasmic filamentous structures were not unenveloped myxo, or retroviral strands (587ab,588), but products of the endoplasmic reticulum in response to IFNαβ oversecretion, serological and biochemical evidence for a herpesvirus (EBV) triggering the maturation of endogenous retrovirus(es) is becoming steadily more convincing throughout of the passing decades (62, 152, 474) .
One would expect that the chronic (but selfdirected) immune reactions would increase the incidence of malignant tumors, especially those of the lymphatic system. Increased lymphomagenesis in patients with autoimmune diseases (lupus) is well confirmed. The incidence of parotid gland marginal zone lymphoma in patients with Sjøgren's syndrome is 1000 fold increased. In SLE, lymphomagenesis is minimally (3fold) increased (589) . Further, it is suspected, but not proven, that EBV in the background, and sporadic buddings of endogenous retroviruses in the lymphoma cells in the foreground, are the etiological agents (178) . Unexpectedly, there is lower incidence of adenocarcinomas (breast, colon, prostate) against the background of a bona fide autoimmune disease, treated or untreated (590, 591) . The German Cancer Research Center in Heidelberg suggests that the natural risk for cancers in autoimmune diseases is increased, but is artificially reduced by suppressing the inflammatory component of cancer induction by anti inflammatory medications (592) . MicroRNA155 emerges as one of the master regulators of immune cell generation, as it has the ability to target mRNAs of a wide variety of the cellular immune system. Should a lymphoid cell population turn malignant, miR155 may be able to suppress its mRNAs (593 Reactive oxygen species and related genotoxic events. Positive comments on inflammatory carcinogenesis based on dsDNA damage (breaks, mutations) by reactive oxygen and nitrogen species abound in the literature (596598). Followers of Professore Flaviano Magrassi, distinguished member of the 'Accademia Nazionale dei Lincei', from Naples, Italy, state 'A mutated cell is a sine qua non for carcinogenesis' (596) . Hypoxia, DNA damage and genome instability; DNA breaks misrepaired (in the form of fusions of distant genes); aging and cancer; the necessity of G proteincoupled receptor for p53dependent cell survival in response to genotoxic stress; nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation and cancer; aldehyde dehydrogenaseexpressing colon stem cells contributing to tumorigenesis in the transition from colitis to cancer; high mobility group A1 gene: transforming inflammatory signals into cancer; oxidative stressing in prostate cancer is required for aggressive phenotype; role of IAPs in NFκB activation by genotoxic stresses; mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer motility through CXCL14; tyrosine kinase cSrc in the regulation of reactive oxygen species generation; role of mismatch repair in the control of oxidative DNA damage; genetic instability and tumorigenesis; induction of epigenetic alterations by chronic inflammation and its significance in carcinogenesis, are the long list of topics recommended for review from the Epub service. Indeed, a high innate production of proinflammatory cytokines was a signal for increased risk for death from cancer (599) .
Oxidative DNA damage occurs consequentially to 'leaks' from electron transport chains. Leak electrons acting with oxygen produce superoxides often released in bursts. Certain enzymes also generate superoxides released in bursts. This is the established practice of phagocytic cells for the destruction of pathogens. Peroxisomes practice normal oxidative metabolism. The unintentional oxidative damage to DNA is caused by the highly reactive hydroxyl radicals abstracting H atoms from the methyl groups (CH 3 ) of thymine and from the CH bonds of 2'deoxyribose. Additions to the C5C6 double bond of pyrimidines transforms these into C5OH and C6OH adduct radicals. H atom abstraction from thymine forms an allyl radical. The C5OH adduct radicals are reducers, and the C6OH adduct radicals are oxidizers. Addition of oxygen to C5OH adduct radicals yield C5OH6peroxyl radicals. C5OH6peroxyl radicals eliminate O 2 ··; after reaction with water, thymine and cytosine glycols are formed. Allyl radicals reacting with oxygen form 5hydroxymethyluracil and 5formyluracil. Thymine peroxyl radicals are reduced to hydroxyhydroperoxides decomposing into thymine glycol, and 5hydroxyl and 5formyluracyls and hydroxylmethylhydantoin. In certain early stages, oxidative DNA damage can be repaired. Genome repair begins with the enzymatic reactions: glycolases removing single lesions, or enzymes excising nucleotides. These are highly specific processes, like the removal of purinderived, or pyrimidine derived oxidative lesions. The repair may be defective, but the DNA remains functional. For example, deamination of cytosine to uracil is a promutagenic mistake (600). The glutathione peroxidase gene (GPX1) in the short arm of chromosome 3 frequently suffers loss of heterozygosity (LOH), thus producing a defective enzyme, the gene product protein peroxide scavenging enzyme (600) .
These events occur when the repair genes suffered SNP (vide supra). In response, mammalian cells express stressinduced genes encoding antioxidant reactions. However, further reactions along these lines leave the DNA molecule either mutated or nonfunctional. The scientific community hypothesizes that if the mutated cells are not eliminated by the 'guardian of the genome', the WTp53 proapoptotic machinery, mismatched repairs and gene fusions may resurrect the damaged cell in a shape and condition not fit into the orderly operation of a multicellular organisms, as if the resurrected cell would not fit into an organized cell community, but could live as a unicellular organism on its own. For example in a tissue culture vessel nourished and cleansed. Under these circumstances it would prove itself to be exempt of senescence and natural death. Its DNA would dictate incessant cell divisions 'forever'. This author, growing EBV + human lymphoblasts in suspension cultures and sarcoma and melanoma cells in solid cultures for over a decade, wrote in 1976 (321,601a): 'Could the cancer cell be viewed as an individual that extricated itself from boundaries exposed (imposed) on it by 500 millions years (3 billion) of evolution and recaptured the immortality of unicellular organisms that existed before the social order of cell communities was estab-lished? Certainly, some cell cultures of mammals, including man, create the impression of immortality of archaic unicellular life forms (i.e., lymphoblastic cells grown in suspension culture as long as nutrients are provided and metabolic waste is removed)' (601a). However, if the resurrected cell remains in its cell community, it may be attacked and killed. It may be able to evade such attacks and continue to replicate and eventually consume its host, as if it were an alien invader (601a).
'Demonstrating a link between defects in repair of oxidative DNA damage and a propensity for disease has not been easy'. Carcinogenesis probably requires combined gene mutations or knockouts. 'The mere presence of damage is not proof of a causative link' (600), a scientifically justified most cautious comment in 2003; by 2010 the evidence for a positive relationship between inflammatory processes and carcinogenesis has reached an overwhelming volume and quality (599) .
The empress (RNA) and the emperor (DNA) of all molecules. The ancient RNA/DNA interactions continue in the most complex intracellular environments. The position of the stem cell gene Sox2 residing embedded in a long noncoding RNA strand (359) , strongly suggests that such constellations might have already been formed in the precellular era on Earth. The microRNAs retain the power over DNA as they are capable of silencing the mRNAs of DNAderivation. Actually, the microRNAs cooperate with the DNA, when the stem cell or somatic cellserving DNA genome transforms itself into a set of multiple oncogenes, thus preventing the cells' senescence and death. It may appear as if the microRNAs dictated the reversal of the cellserving DNA into its primordial 'immortal' format (vide infra). The stem cells may rest, selfrenew, yield daughter cells for specific differentiation in the form of functional somatic cells, or transform toward immortalized cell populations, whereby the DNA genome undergoes ds breaks; misrepaired, the dsDNA breaks result in gene fusions and oncogene formations, while genes inhibitory to this process (the 'tumor suppressor genes') are deleted. Inflammatory processes frequently signal the stem cell (or the differentiated somatic cell) toward the latter pathway. It appears as if microRNAs guide the DNA toward which way to go. Thus inflammatory reactions indirectly through miRmediation penetrate the epigenome and act through its modification. A scholarly review spreads the word in Hungarian (so convincingly, as if the crosstalk between RNA and DNA actually went on in Hungarian) (601b). Indeed, the ancient RNA/DNA crosstalk should be understood in all languages. It is spelling out the verdict of life or death for the cell, from the time on, since cells lived on Earth. The extraordinary versatility of the DNA in its transformation into sets of oncogenes and its interaction with the epigenome in the process was well recognized even before the discovery of the microRNAs (602) .
The question arises if it is not so, that hyperthermia (HSF), hypoxia (HIF), reactive oxygen/nitrogen species (ROS, iNOS) and stress, and showers of inflammatory cytokines release their danger signaling to the RNA/DNA complex. The somatic cell serving DNA in multicellular organisms accepted senescence and death, but retained suppressed but preserved, its primordial faculties of independence and 'immortality' in the germ cells and in the stem cells. The haploid germ cells in their unisons become differentiating somatic cells. However, the selfrenewing stem cells, instead of the route to differentiation, may choose a reversal toward a primordial stage of life: restoring the ancient DNA and the ways it existed under precellular conditions intimately reacting with RNA and with 'amorphous proteins', as amino acid chains 'selfreplicating' (603, 604) . In the first cellular life forms, DNA was highly resistant to physicochemical damage and voraciously accepting for fusion and recombination alien genomic sequences (62) . Upon the encounter of amorphous proteins and naked DNA, the proteins engulf the DNA and DNA strands penetrate to the helices of the proteins, while the proteins undergo subtle morphological changes of their nanoparticulate architecture (604) . Innumerable such newly formed structures may exist in nature without being able to enter cells for replications, inasmuch as the natural proteins can not serve as specific ligands to any cell receptors (whereas, the proteins generated in the DomingoEspin laboratory were actually encoded by borrowed viral genes from the foot and mouth virus and from the SV40 virus, and thus have become 'artificial viruses' able to react with cell and nuclear membrane receptors and transgress them) (604) . In contrast, the natutally formed entities may show up in the metagenomic samples (in a mixture with regular incomplete virions), as the 'gene transfer agents' of Kristensen et al (605) , or among the structures considered to form a 'fourth domain of life' on Earth (606) .
The spheroplasts of a crenarchaeota and a prokaryota might have been fused by a fusogenic phage of an ancestral mycoplasma (like that of the Acheloplasma sp) to form the first eukaryotic cells (an experiment of Nature that could be repeated in the lab today) (607) . Since their origin by cell fusion, eukaryotic cells continue to readily communicate through cell fusions in physiological or oncogenic terms; all oncogenic viruses are able to fuse cells (62, 608, 609) . Lymphoma cells naturally fused with specific antibodyproducer plasma cells (referred later to as 'natural hybridomas') discovered in mice in the late1960's are presumed to exist in human patients (62, 225, 610614) . In the first unicellular nucleated eukaryotes, with or without the acquisition of mitochondria or chloroplasts, the RNA/DNA complex maintained its superiority over all other molecules, either within the cell, or outside the cell, as phages converted into RNA ('the burst' of picornaviruses) (615) , and into DNA eukaryotic viruses (616) . Those sophisticated cells divided before senescence and death; natural death was not encrypted in their DNA genomes. In adverse circumstances, the most versatile ancient DNA transformed them into morphological and physiological entities grossly different from their basic original life forms: as if into a different (from an aflagellate to a flagellate) species. The Naegleria DNA still practices such transformations of its host (617, 618) . Later, in the unicellular parasite Theileria under immunological attack in an invaded bovine host, the most versatile theileria DNA encodes an elaborate physiology for the parasite to evade that immunological attack from its host (619) . In the theileriainduced fatal lymphoproliferative disease, the East Coast fever, the parasite induces NFκB to secure apoptosisfree state of the schizontinfected lymphocytes. Theileriainfected macrophages bring into existence an autocrine loop for TGFβ2 and induce MMP9 for their survival and invasiveness (620, 621) , thus using the same molecular mechanisms cancer cells utilize for their survival and invasiveness. In the glioblastoma cell, the DNA can switch from the anaerobic glycolysis to oxidative phosphorylation and metabolism (622) .
The Namalwa Burkitt's lymphoma cell DNA under attack with heavy irradiation, suffers severe ds breaks. The γH2AX (ataxia) histone detects an extraordinarily high incidence of these ds breaks. However, the oncogenic DNA (with the help of repair enzymes like the recombinase Rad51, forming nucleoprotein complexes from ss/ds broken DNA sequences) recovers from the 'mitotic catastrophe' (623) . In the enzyme free (except for the ribozymes) precellular RNA/DNA world, ss or dsRNA/DNA breaks might have been repaired telomere free by endtoend seals (which are chromosome fusions in the celluler world) (624) .
The existence of viral genes related to RNA/DNA replication, but not shared with cellular genes (the 'viral hallmark genes' of Koonin et al, vide infra) strongly suggests that the origin of these genes predates the appearance of protocells (625) . For selfreplicating macromolecules in hypercycles (a symbiosis of molecules selfreplicating in hypercycles, Ghadiri et al, vide infra), the Eigen's error catastrophe phase transited into a thermodynamic phase governing templated RNA/DNA synthesis (626) .
Following the ideas of oldtime astute observers, Arguello proposes that the cancer cell is the result of an 'atavistic metamorphosis' (627a). Duesberg et al (627b) consider the cancer cell to be the product of a transspeciation process.
The oncogenic DNA bioengineers the neoplastic cell as its ancestors could (and still do) bioengineer the naegleria cell, while it remains close to indestructible, as its predecessor, the primordial DNA, must have been (628) . Are oncogenes representing a reversal of the cellserving DNA to its primordial format? Is the multiply fused and most powerful oncogenic DNA a replica of the primordial DNA? Is it not so, that the malady that we diagnose as 'cancer', is the expression of an inherent fundamental attribute of the DNA, its reversal from the differentiated to the native undifferentiated format in order to sustain life under any conditions and in any shape (628)? Were it not our killer, scientists would admire the cancer cell and its DNA 'oncogenes' as the ultimate achievement of bioengineering.
A 'precellular virus world' and a 'primordial gene pool' could have formed on Earth (629) . That world can not only be imagined, but could possibly be duplicated in the laboratory. How the naked DNAs interacted with amorphous amino acid clusters (603, 604) , hypercycling RNAs in the hydrothermal vents at the bottom of the oceans (and in their laboratory reactors) (630) , the catalytic hammerhead ribozymes (631) , and the circular selfreplicating ('rolling circle') viroid RNAs (preserved from the precellular world in extant plant and mammalian cells, the hepatitis δ viroid, some with a tandemly repeated homologous DNA attached) (632635)? In order to envision these interactions in a most hostile precellular environment without potent protein enzymes, that were not being able to form without cellular ribosomes and without a genetic code, both advanced knowledge in proteomics and genomics, and a great deal of imagination, are required. This author for one, subscribes with gratitude the review, Professor W. Ford Doolittle (Dalhouise University, Halifax, Nova Scotia, Canada) rendered, to Koonin et al: 'Viruslike entities surely predated the appearance of modern cells…Evolutionary scenarios are an artform. They usefully exercise the brain…They do not have to be true! I do not disfavor the publication…' (629).
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